Abbreviations	
SD	Standard deviation
IQR	Interquartile range (first to third quartile)
NA.	Missing data
N/A	Not applicable

2. Where in the UK is your Lab?

2. Where in the UK is your Lab?	Overall	
	n	% (N = 15)
England	15	100%
NA.	0	-

3. How would you categorise your hospital?

3. How would you categorise your hospital?	Overall	
	n	% (N = 15)
Other	1	7%
Regional Centre	14	93%
NA.	0	-

4. What region does your lab cover for diagnosis and management of cancer samples?

4. What region does your lab cover for diagnosis and management of cancer samples?	Overall	
	n	% (N = 15)
Referal network	15	100%
NA.	0	-

4. Estimated population size (in million)

4. Estimated population size (in million)	Overall
	N = 15
Mean	3.3
SD	2.9
Median	2.5
IQR	1.9 to 3.6
Range	1 to 12
NA.	3

5. Which is your regional GLH or genomics centre?

5. Which is your regional GLH or genomics centre?	Overall	
	n	% (N = 15)
Central and South GLH	3	20%
Central and South GLH + North Thames GLH	1	7%
East GLH	2	13%
North East & Yorkshire GLH	2	13%
North Thames GLH	2	13%
North West GLH	3	20%
South West GLH	2	13%
NA.	0	-

6. IHC

6. IHC	Overall	
	n	% (N = 15)
Yes	15	100%
NA.	0	-

6. FISH

6. FISH	Overall	
	n	% (N = 15)
No	11	73%
Yes	4	27%
NA.	0	-

6. RT-PCR

6. RT-PCR	Overall	
	n	% (N = 15)
No	6	40%
Yes	9	60%
NA.	0	-

6. Sanger Sequencing

6. Sanger Sequencing	Overall	
	n	% (N = 15)
No	13	87%
Yes	2	13%
NA.	0	-

6. NGS

6. NGS	Overall	
	n	% (N = 15)
No	13	87%
Yes	2	13%
NA.	0	-

6. Other

6. Other	Overall	
	n	% (N = 1)
Pyro sequencing & digital based (AI) assessment of proteins	1	100%
NA.	14	-

7. Breast

7. Breast	Overall
	N = 15

Mean	234.4
SD	229.8
Median	130
IQR	40 to 425
Range	35 to 600
NA.	7

7. Lung

7. Lung	Overall
	N = 15
Mean	112.9
SD	143.1
Median	65
IQR	30 to 100
Range	20 to 500
NA.	0

7 . Melanoma Skin

7 . Melanoma Skin	Overall
	N = 15
Mean	87.9
SD	96.7
Median	52.5
IQR	20 to 105
Range	18 to 300
NA.	7

7. Other Cancers

7. Other Cancers	Overall
	N = 15
Mean	183.3
SD	104.1
Median	150
IQR	125 to 225
Range	100 to 300
NA.	12

IHC: Reflex at diagnosis - HR

IHC: Reflex at diagnosis - HR	Overall	
	n	% (N = 9)
Yes	9	100%
NA.	0	-

IHC: Reflex at diagnosis - HER2

IHC: Reflex at diagnosis - HER2	Overall	
	n	% (N = 9)
Yes	9	100%
NA.	0	-

IHC: Reflex at diagnosis - PGR

IHC: Reflex at diagnosis - PGR	Overall	
	n	% (N = 9)
On request	1	11%
Yes	8	89%
NA.	0	-

IHC: Reflex at diagnosis - PD-L1

IHC: Reflex at diagnosis - PD-L1	Overall	
	n	% (N = 9)
No	2	22%
On request	4	44%
Yes	3	33%
NA.	0	-

IHC: Reflex at diagnosis - NTRKfus

IHC: Reflex at diagnosis - NTRKfus	Overall	
	n	% (N = 9)
No	5	56%
On request	4	44%
NA.	0	-

IHC: Testing at progression/ relapse/ other post Dx timepoints - HR

IHC: Testing at progression/ relapse/ other post Dx timepoints - HR	Overall	
	n	% (N = 9)
No	4	44%
On request	1	11%
Yes	4	44%
NA.	0	-

IHC: Testing at progression/ relapse/ other post Dx timepoints - HER2

IHC: Testing at progression/ relapse/ other post Dx timepoints - HER2	Overall	
	n	% (N = 9)
No	4	44%
Yes	5	56%
NA.	0	-

IHC: Testing at progression/ relapse/ other post Dx timepoints - PGR

IHC: Testing at progression/ relapse/ other post Dx timepoints - PGR	Overall	
	n	% (N = 9)
No	4	44%
Yes	5	56%
NA.	0	-

IHC: Testing at progression/ relapse/ other post Dx timepoints - PD-L1

IHC: Testing at progression/ relapse/ other post Dx timepoints - PD-L1	Overall	
	n	% (N = 9)
No	3	33%
On request	3	33%
Yes	3	33%
NA.	0	-

IHC: Testing at progression/ relapse/ other post Dx timepoints - NTRKfus

IHC: Testing at progression/ relapse/ other post Dx timepoints - NTRKfus	Overall	
	n	% (N = 9)
No	5	56%
On request	4	44%
NA.	0	-

IHC: Performed by pathology lab - HR

IHC: Performed by pathology lab - HR	Overall	
	n	% (N = 9)
Yes	9	100%
NA.	0	-

IHC: Performed by pathology lab - HER2

IHC: Performed by pathology lab - HER2	Overall	
	n	% (N = 9)
Other external lab	2	22%
Yes	7	78%
NA.	0	-

IHC: Performed by pathology lab - PGR

IHC: Performed by pathology lab - PGR	Overall	
	n	% (N = 9)
Yes	9	100%
NA.	0	-

IHC:Performed by pathology lab - PD-L1

IHC:Performed by pathology lab - PD-L1	Overall	
	n	% (N = 8)
Other external lab	2	25%

Yes	6	75%
NA.	1	-

IHC: Performed by pathology lab - NTRKfus

IHC: Performed by pathology lab - NTRKfus	Overall	
	n	% (N = 4)
No	2	50%
Other external lab	1	25%
Yes	1	25%
NA.	5	-

IHC: Moved to GLH/ Genomic centre - HR

IHC: Moved to GLH/ Genomic centre - HR	Overall	
	n	% (N = 9)
No	9	100%
NA.	0	-

IHC: Moved to GLH/ Genomic centre - HER2

IHC: Moved to GLH/ Genomic centre - HER2	Overall	
	n	% (N = 9)
No	9	100%
NA.	0	-

IHC: Moved to GLH/ Genomic centre - PGR

IHC: Moved to GLH/ Genomic centre - PGR	Overall	
	n	% (N = 9)
No	9	100%
NA.	0	-

IHC: Moved to GLH/ Genomic centre - PD-L1

IHC: Moved to GLH/ Genomic centre - PD-L1	Overall	
	n	% (N = 8)
No	8	100%
NA.	1	-

IHC: Moved to GLH/ Genomic centre - NTRKfus

IHC: Moved to GLH/ Genomic centre - NTRKfus	Overall	
	n	% (N = 4)
No	2	50%
Yes	2	50%
NA.	5	-

IHC: Moving to GLH/ Genomic hubs - HR

IHC: Moving to GLH/ Genomic hubs - HR	Overall	
	n	% (N = 9)
No	9	100%
NA.	0	-

IHC: Moving to GLH/ Genomic hubs - HER2

IHC: Moving to GLH/ Genomic hubs - HER2	Overall	
	n	% (N = 9)
No	9	100%
NA.	0	-

IHC: Moving to GLH/ Genomic hubs - PGR

IHC: Moving to GLH/ Genomic hubs - PGR	Overall	
	n	% (N = 9)
No	9	100%
NA.	0	-

IHC: Moving to GLH/ Genomic hubs - PD-L1

IHC: Moving to GLH/ Genomic hubs - PD-L1	Overall	
	n	% (N = 8)
No	8	100%
NA.	1	-

IHC: Moving to GLH/ Genomic hubs - NTRKfus

IHC: Moving to GLH/ Genomic hubs - NTRKfus	Overall	
	n	% (N = 4)
No	4	100%
NA.	5	-

IHC: Current Average Turnaround time - HR

IHC: Current Average Turnaround time - HR	Overall
	N = 9
Mean	2.1
SD	0.6
Median	2
IQR	2 to 2.2
Range	1 to 3
NA.	1

IHC: Current Average Turnaround time - HER2

IHC: Current Average Turnaround time - HER2	Overall
	N = 9
Mean	2.9
SD	1.1
Median	2.8
IQR	2 to 3.2
Range	2 to 5
NA.	1

IHC: Current Average Turnaround time - PGR

IHC: Current Average Turnaround time - PGR	Overall
	N = 9
Mean	2.2

SD	0.7
Median	2
IQR	2 to 2.6
Range	1 to 3
NA.	1

IHC: Current Average Turnaround time - PD-L1

IHC: Current Average Turnaround time - PD-L1	Overall
	N = 9
Mean	8.7
SD	10.6
Median	3
IQR	2.2 to 11.2
Range	1 to 30
NA.	2

IHC: Current Average Turnaround time - NTRKfus

IHC: Current Average Turnaround time - NTRKfus	Overall
	N = 9
Mean	19
SD	10.1
Median	19.2
IQR	12.4 to 25.9
Range	7.5 to 30
NA.	5

FISH: Reflex at diagnosis - HER2

FISH: Reflex at diagnosis - HER2	Overall	
	n	% (N = 9)
No	1	11%
On request	2	22%
Yes	6	67%
NA.	0	-

FISH: Reflex at diagnosis - NTRKfus

FISH: Reflex at diagnosis - NTRKfus	Overall	
	n	% (N = 9)
No	6	67%
On request	3	33%
NA.	0	-

FISH:Testing at progression/ relapse/ other post Dx timepoints - HER2

FISH:Testing at progression/ relapse/ other post Dx timepoints - HER2	Overall	
	n	% (N = 9)
No	5	56%
On request	1	11%
Yes	3	33%
NA.	0	-

FISH: Testing at progression/ relapse/ other post Dx timepoints - NTRKfus

FISH: Testing at progression/ relapse/ other post Dx timepoints - NTRKfus	Overall	
	n	% (N = 9)
No	5	56%
On request	3	33%
Yes	1	11%
NA.	0	-

FISH: Performed by pathology lab - HER2

FISH: Performed by pathology lab - HER2	Overall	
	n	% (N = 8)
No	3	38%
Other external lab	1	12%
Yes	4	50%
NA.	1	-

FISH: Performed by pathology lab - NTRKfus

FISH: Performed by pathology lab - NTRKfus	Overall	
	n	% (N = 4)
No	3	75%
Other external lab	1	25%
NA.	5	-

FISH: Moved to GLH/ Genomic centre - HER2

FISH: Moved to GLH/ Genomic centre - HER2	Overall	
	n	% (N = 8)
No	5	62%
Yes	3	38%
NA.	1	-

FISH: Moved to GLH/ Genomic centre - NTRKfus

FISH: Moved to GLH/ Genomic centre - NTRKfus	Overall	
	n	% (N = 4)
No	1	25%
Yes	3	75%
NA.	5	-

FISH: Moving to GLH/ Genomic hubs - HER2

FISH: Moving to GLH/ Genomic hubs - HER2	Overall	
	n	% (N = 8)
No	8	100%
NA.	1	-

FISH: Moving to GLH/ Genomic hubs - NTRKfus

FISH: Moving to GLH/ Genomic hubs - NTRKfus	Overall	
	n	% (N = 4)
No	4	100%
NA.	5	-

FISH: Current Average Turnaround time - HER2

FISH: Current Average Turnaround time - HER2	Overall
	N = 9

Mean	7.2
SD	4.5
Median	7
IQR	3.5 to 10.2
Range	2 to 14
NA.	2

FISH: Current Average Turnaround time - NTRKfus

FISH: Current Average Turnaround time - NTRKfus	Overall
	N = 9
Mean	23.2
SD	6.7
Median	24.5
IQR	21.9 to 25.9
Range	14 to 30
NA.	5

RT-PCR: Reflex at diagnosis - PIK3CA

RT-PCR: Reflex at diagnosis - PIK3CA	Overall	
	n	% (N = 9)
No	6	67%
On request	3	33%
NA.	0	-

RT-PCR: Reflex at diagnosis - BRCA 1/2

RT-PCR: Reflex at diagnosis - BRCA 1/2	Overall	
	n	% (N = 9)
No	8	89%
Yes	1	11%
NA.	0	-

RT-PCR: Reflex at diagnosis - NTRKfus

RT-PCR: Reflex at diagnosis - NTRKfus	Overall	
	n	% (N = 9)
No	6	67%
On request	3	33%
NA.	0	-

RT-PCR: Testing at progression/ relapse/ other post Dx timepoints - PIK3CA

RT-PCR: Testing at progression/ relapse/ other post Dx timepoints - PIK3CA	Overall	
	n	% (N = 9)
No	7	78%
On request	2	22%
NA.	0	-

RT-PCR: Testing at progression/ relapse/ other post Dx timepoints - BRCA 1/2

RT-PCR: Testing at progression/ relapse/ other post Dx timepoints - BRCA 1/2	Overall	
	n	% (N = 9)
No	8	89%
Yes	1	11%
NA.	0	-

RT-PCR: Testing at progression/ relapse/ other post Dx timepoints - NTRKfus

RT-PCR: Testing at progression/ relapse/ other post Dx timepoints - NTRKfus	Overall	
	n	% (N = 9)
No	6	67%
On request	3	33%
NA.	0	-

RT-PCR: Performed by pathology lab - PIK3CA+BE4

RT-PCR: Performed by pathology lab - PIK3CA+BE4	Overall	
	n	% (N = 4)
No	3	75%
Yes	1	25%
NA.	5	-

RT-PCR: Performed by pathology lab - BRCA 1/2

RT-PCR: Performed by pathology lab - BRCA 1/2	Overall	
	n	% (N = 2)
No	2	100%
NA.	7	-

RT-PCR: Performed by pathology lab - NTRKfus

RT-PCR: Performed by pathology lab - NTRKfus	Overall	
	n	% (N = 4)
No	3	75%
Yes	1	25%
NA.	5	-

RT-PCR: Moved to GLH/ Genomic centre - PIK3CA

RT-PCR: Moved to GLH/ Genomic centre - PIK3CA	Overall	
	n	% (N = 4)
No	1	25%
Yes	3	75%
NA.	5	-

RT-PCR: Moved to GLH/ Genomic centre - BRCA 1/2

RT-PCR: Moved to GLH/ Genomic centre - BRCA 1/2	Overall	
	n	% (N = 2)
Yes	2	100%
NA.	7	-

RT-PCR: Moved to GLH/ Genomic centre - NTRKfus

RT-PCR: Moved to GLH/ Genomic centre - NTRKfus	Overall	
	n	% (N = 4)
No	1	25%

Yes	3	75%
NA.	5	-

RT-PCR: Moving to GLH/ Genomic hubs - PIK3CA

RT-PCR: Moving to GLH/ Genomic hubs - PIK3CA	Overall	
	n	% (N = 4)
No	4	100%
NA.	5	-

RT-PCR: Moving to GLH/ Genomic hubs - BRCA 1/2

RT-PCR: Moving to GLH/ Genomic hubs - BRCA 1/2	Overall	
	n	% (N = 2)
No	2	100%
NA.	7	-

RT-PCR: Moving to GLH/ Genomic hubs - NTRKfus

RT-PCR: Moving to GLH/ Genomic hubs - NTRKfus	Overall	
	n	% (N = 4)
No	4	100%
NA.	5	-

RT-PCR: Current Average Turnaround time - PIK3CA

RT-PCR: Current Average Turnaround time - PIK3CA	Overall
	N = 9
Mean	17.2
SD	11.6
Median	14
IQR	10.8 to 22
Range	7.5 to 30
NA.	6

RT-PCR: Current Average Turnaround time - BRCA 1/2

RT-PCR: Current Average Turnaround time - BRCA 1/2	Overall
	N = 9
Mean	15
SD	
Median	15
IQR	15 to 15
Range	15 to 15
NA.	8

RT-PCR: Current Average Turnaround time - NTRKfus

RT-PCR: Current Average Turnaround time - NTRKfus	Overall
	N = 9
Mean	17.5
SD	11.5
Median	15
IQR	11.2 to 22.5
Range	7.5 to 30
NA.	6

NGS: Reflex at diagnosis - PIK3CA

NGS: Reflex at diagnosis - PIK3CA	Overall	
	n	% (N = 9)
No	7	78%
On request	1	11%
Test Done - Timeline unknown	1	11%
NA.	0	-

NGS: Reflex at diagnosis - HER2

NGS: Reflex at diagnosis - HER2	Overall	
	n	% (N = 9)
No	8	89%
Test Done - Timeline unknown	1	11%
NA.	0	-

NGS: Reflex at diagnosis - NTRKfus

NGS: Reflex at diagnosis - NTRKfus	Overall	
	n	% (N = 9)
No	5	56%

On request	2	22%
Test Done - Timeline unknown	1	11%
Yes	1	11%
NA.	0	-

NGS: Reflex at diagnosis - BRCA 1/2

NGS: Reflex at diagnosis - BRCA 1/2	Overall	
	n	% (N = 9)
No	6	67%
On request	2	22%
Test Done - Timeline unknown	1	11%
NA.	0	-

NGS: Testing at progression/ relapse/ other post Dx timepoints - PIK3CA

NGS: Testing at progression/ relapse/ other post Dx timepoints - PIK3CA	Overall	
	n	% (N = 9)
No	7	78%
On request	1	11%
Test Done - Timeline unknown	1	11%
NA.	0	-

NGS: Testing at progression/ relapse/ other post Dx timepoints - HER2

NGS: Testing at progression/ relapse/ other post Dx timepoints - HER2	Overall	
	n	% (N = 9)
No	8	89%
Test Done - Timeline unknown	1	11%
NA.	0	-

NGS: Testing at progression/ relapse/ other post Dx timepoints - NTRKfus

NGS: Testing at progression/ relapse/ other post Dx timepoints - NTRKfus	Overall	
	n	% (N = 9)
No	4	44%
On request	2	22%
Test Done - Timeline unknown	1	11%
Yes	2	22%
NA.	0	-

NGS: Testing at progression/ relapse/ other post Dx timepoints - BRCA 1/2

NGS: Testing at progression/ relapse/ other post Dx timepoints - BRCA 1/2	Overall	
	n	% (N = 9)
No	5	56%
On request	2	22%
Test Done - Timeline unknown	1	11%
Yes	1	11%
NA.	0	-

NGS: Performed by pathology lab - PIK3CA

NGS: Performed by pathology lab - PIK3CA	Overall	
	n	% (N = 2)
No	2	100%
NA.	7	-

NGS: Performed by pathology lab - HER2

NGS: Performed by pathology lab - HER2	Overall	
	n	% (N = 1)
No	1	100%
NA.	8	-

NGS: Performed by pathology lab - NTRKfus

NGS: Performed by pathology lab - NTRKfus	Overall	

	n	% (N = 5)
No	4	80%
Yes	1	20%
NA.	4	-

NGS: Performed by pathology lab - BRCA 1/2

NGS: Performed by pathology lab - BRCA 1/2	Overall	
	n	% (N = 4)
No	4	100%
NA.	5	-

NGS: Moved to GLH/ Genomic centre - PIK3CA

NGS: Moved to GLH/ Genomic centre - PIK3CA	Overall	
	n	% (N = 2)
Yes	2	100%
NA.	7	-

NGS: Moved to GLH/ Genomic centre - HER2

NGS: Moved to GLH/ Genomic centre - HER2	Overall	
	n	% (N = 1)
Yes	1	100%
NA.	8	-

NGS: Moved to GLH/ Genomic centre - NTRKfus

NGS: Moved to GLH/ Genomic centre - NTRKfus	Overall	
	n	% (N = 5)
No	1	20%
Yes	4	80%
NA.	4	-

NGS: Moved to GLH/ Genomic centre - BRCA 1/2

NGS: Moved to GLH/ Genomic centre - BRCA 1/2	Overall	
	n	% (N = 4)
Yes	4	100%
NA.	5	-

NGS: Moving to GLH/ Genomic hubs - PIK3CA

NGS: Moving to GLH/ Genomic hubs - PIK3CA	Overall	
	n	% (N = 2)
No	2	100%
NA.	7	-

NGS: Moving to GLH/ Genomic hubs - HER2

NGS: Moving to GLH/ Genomic hubs - HER2	Overall	
	n	% (N = 1)
No	1	100%
NA.	8	-

NGS: Moving to GLH/ Genomic hubs - NTRKfus

NGS: Moving to GLH/ Genomic hubs - NTRKfus	Overall	
	n	% (N = 5)
No	5	100%
NA.	4	-

NGS: Moving to GLH/ Genomic hubs - BRCA 1/2

NGS: Moving to GLH/ Genomic hubs - BRCA 1/2	Overall	
	n	% (N = 4)
No	4	100%
NA	5	

NGS: Current Average Turnaround time - PIK3CA

NGS: Current Average Turnaround time - PIK3CA	Overall
	N = 9
Mean	40
SD	
Median	40
IQR	40 to 40
Range	40 to 40
NA.	8

NGS: Current Average Turnaround time - NTRKfus

NGS: Current Average Turnaround time - NTRKfus	Overall
	N = 9
Mean	26.1
SD	10.2
Median	24.5
IQR	22.2 to 28.4
Range	15.5 to 40
NA.	5

NGS: Current Average Turnaround time - BRCA 1/2

NGS: Current Average Turnaround time - BRCA 1/2	Overall	
	N = 9	
Mean	29.6666667	
SD	8.9	
Median	24.5	
IQR	24.5 to 32.2	
Range	24.5 to 40	
NA.	6	

24.5 24.5 40

Others

Others	Overall	
	n	% (N = 9)
ki67 (IHC)	1	11%
N/A	5	56%
ONCOTYPE DX	3	33%
NA.	0	-

Reflex at diagnosis - ONCOTYPE DX

Reflex at diagnosis - ONCOTYPE DX	Overall	
	n	% (N = 9)
N/A	6	67%
Not specified	2	22%
On request	1	11%
NA.	0	-

Testing at progression/ relapse/ other post Dx timepoints - ONCOTYPE DX

Testing at progression/ relapse/ other post Dx timepoints - ONCOTYPE DX	Overall	
	n	% (N = 9)
N/A	6	67%
Not specified	2	22%
On request	1	11%
NA.	0	-

Performed by pathology lab - ONCOTYPE DX

Performed by pathology lab - ONCOTYPE DX	Overall	
	n	% (N = 9)
N/A	6	67%
Other external lab	3	33%
NA.	0	-

Moved to GLH/ Genomic centre - ONCOTYPE DX

Moved to GLH/ Genomic centre - ONCOTYPE DX	Overall	
	n	% (N = 9)
N/A	6	67%
No	3	33%
NA.	0	-

Moving to GLH/ Genomic hubs - ONCOTYPE DX

Moving to GLH/ Genomic hubs - ONCOTYPE DX	Overall	
	n	% (N = 9)

N/A	6	67%
No	3	33%
NA.	0	-

Current Average Turnaround time (calendar days) - ONCOTYPE DX

Current Average Turnaround time (calendar days) - ONCOTYPE DX	Overall	
	n	% (N = 9)
24.5	1	11%
N/A	6	67%
Not specified	2	22%
NA.	0	-

Reflex at diagnosis - ki67 (IHC)

Reflex at diagnosis - ki67 (IHC)	Overall	
	n	% (N = 9)
N/A	8	89%
Yes	1	11%
NA.	0	-

Testing at progression/ relapse/ other post Dx timepoints - ki67 (IHC)

Testing at progression/ relapse/ other post Dx timepoints - ki67 (IHC)	Overall	
	n	% (N = 9)
N/A	8	89%
No	1	11%
NA.	0	-

Performed by pathology lab - ki67 (IHC)

Performed by pathology lab - ki67 (IHC)	Overall	
	n	% (N = 9)
N/A	8	89%
Yes	1	11%
NA.	0	-

Moved to GLH/ Genomic centre - ki67 (IHC)

Moved to GLH/ Genomic centre - ki67 (IHC)	Overall	
	n	% (N = 9)
N/A	8	89%
No	1	11%
NA.	0	-

Moving to GLH/ Genomic hubs - ki67 (IHC)

Moving to GLH/ Genomic hubs - ki67 (IHC)	Overall	
	n	% (N = 9)
N/A	8	89%
No	1	11%
NA.	0	-

Current Average Turnaround time (calendar days) - ki67 (IHC)

Current Average Turnaround time (calendar days) - ki67 (IHC)	Overall	
	n	% (N = 9)
N/A	8	89%
Not known	1	11%
NA.	0	-

IHC: Reflex at diagnosis - PD-L1

IHC: Reflex at diagnosis - PD-L1	Overall	
	n	% (N = 15)
Yes	15	100%
NA.	0	-

IHC: Reflex at diagnosis - ROS1fus

IHC: Reflex at diagnosis - ROS1fus	Overall	
	n	% (N = 15)
No	2	13%
Yes	13	87%
NA.	0	-

IHC: Reflex at diagnosis - ALKfus

IHC: Reflex at diagnosis - ALKfus	Overall	
	n	% (N = 15)
On request	1	7%
Yes	14	93%
NA.	0	-

IHC: Reflex at diagnosis - BRAF

IHC: Reflex at diagnosis - BRAF	Overall	
	n	% (N = 15)
No	14	93%
Yes	1	7%
NA.	0	-

IHC: Reflex at diagnosis - NTRKfus

IHC: Reflex at diagnosis - NTRKfus	Overall	
	n	% (N = 15)
No	12	80%
Yes	3	20%
NA.	0	-

IHC: Testing at progression / relapse / other post Dx timepoints - PD-L1

IHC: Testing at progression / relapse / other post Dx timepoints - PD-L1	Overall	
	n	% (N = 15)
No	4	27%
On request	7	47%
Yes	4	27%
NA.	0	-

IHC: Testing at progression / relapse / other post Dx timepoints ROS1fus

IHC: Testing at progression / relapse / other post Dx timepoints ROS1fus	Overall	
	n	% (N = 15)
No	8	53%
On request	5	33%
Yes	2	13%
NA.	0	-

IHC: Testing at progression / relapse / other post Dx timepoints - ALKfus

IHC: Testing at progression / relapse / other post Dx timepoints - ALKfus	Overall	
	n	% (N = 15)
No	7	47%
On request	6	40%
Yes	2	13%
NA.	0	-

IHC: Testing at progression / relapse / other post Dx timepoints - BRAF

IHC: Testing at progression / relapse / other post Dx timepoints - BRAF	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

IHC: Testing at progression / relapse / other post Dx timepoints - NTRKfus

IHC: Testing at progression / relapse / other post Dx timepoints - NTRKfus	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

IHC: Performed by pathology lab - PD-L1

IHC: Performed by pathology lab - PD-L1	Overall	
	n	% (N = 15)
Other external lab	1	7%
Yes	14	93%
NA.	0	-

IHC: Performed by pathology lab - ROS1fus

IHC: Performed by pathology lab - ROS1fus	Overall	
	n	% (N = 13)
Other external lab	2	15%
Yes	11	85%
NA.	2	-

IHC: Performed by pathology lab - ALKfus

IHC: Performed by pathology lab - ALKfus	Overall	
	n	% (N = 15)
Other external lab	1	7%
Yes	14	93%
NA.	0	-

IHC: Performed by pathology lab - BRAF

IHC: Performed by pathology lab - BRAF	Overall	
	n	% (N = 1)
Yes	1	100%
NA.	14	-

IHC: Performed by pathology lab - NTRKfus

IHC: Performed by pathology lab - NTRKfus	Overall	
	n	% (N = 3)
Other external lab	1	33%
Yes	2	67%
NA.	12	-

IHC: Moved to GLH / Genomic Centre - PD-L1

IHC: Moved to GLH / Genomic Centre - PD-L1	Overall	
	n	% (N = 15)
No	15	100%
NA.	0	-

IHC: Moved to GLH / Genomic Centre - ROS1fus

IHC: Moved to GLH / Genomic Centre - ROS1fus	Overall	
	n	% (N = 13)
No	13	100%
NA.	2	-

IHC: Moved to GLH / Genomic Centre - ALKfus

IHC: Moved to GLH / Genomic Centre - ALKfus	Overall	
	n	% (N = 15)
No	15	100%
NA.	0	-

IHC: Moved to GLH / Genomic Centre - BRAF

IHC: Moved to GLH / Genomic Centre - BRAF	Overall	
	n	% (N = 1)
No	1	100%
NA.	14	-

IHC: Moved to GLH / Genomic Centre - NTRKfus

IHC: Moved to GLH / Genomic Centre - NTRKfus	Overall	
	n	% (N = 3)
No	3	100%
NA.	12	-

IHC: Moving to GLH / Genomic hubs - PL-D1

IHC: Moving to GLH / Genomic hubs - PL-D1	Overall	
	n	% (N = 15)
No	15	100%
NA.	0	-

IHC: Moving to GLH / Genomic hubs - ROS1fus

IHC: Moving to GLH / Genomic hubs - ROS1fus	Overall	
	n	% (N = 13)
No	13	100%
NA.	2	-

IHC: Moving to GLH / Genomic hubs - ALKfus

IHC: Moving to GLH / Genomic hubs - ALKfus	Overall	
	n	% (N = 15)
No	15	100%
NA.	0	-

IHC: Moving to GLH / Genomic hubs - BRAF

IHC: Moving to GLH / Genomic hubs - BRAF	Overall	
	n	% (N = 1)
No	1	100%
NA.	14	-

IHC: Moving to GLH / Genomic hubs - NTRKfus

IHC: Moving to GLH / Genomic hubs - NTRKfus	Overall	

	n	% (N = 3)
No	3	100%
NA.	12	-

IHC: Current average turnaround time - PD-L1

IHC: Current average turnaround time - PD-L1	Overall
	N = 15
Mean	4.9
SD	7.5
Median	2.5
IQR	2 to 3
Range	1 to 30
NA.	1

IHC: Current average turnaround time - ROS1fus

IHC: Current average turnaround time - ROS1fus	Overall
	N = 15
Mean	5.8
SD	8
Median	2.8
IQR	2 to 7
Range	1 to 30
NA.	3

IHC: Current average turnaround time - ALKfus

IHC: Current average turnaround time - ALKfus	Overall
	N = 15
Mean	5.1
SD	7.7
Median	2.5
IQR	2 to 3
Range	1 to 30
NA.	2

IHC: Current average turnaround time - BRAF

IHC: Current average turnaround time - BRAF	Overall
	N = 15

Mean	3
SD	
Median	3
IQR	3 to 3
Range	3 to 3
NA.	14

IHC: Current average turnaround time - NTRKfus

IHC: Current average turnaround time - NTRKfus	Overall
	N = 15
Mean	13.5
SD	14.5
Median	7.5
IQR	5.2 to 18.8
Range	3 to 30
NA.	12

FISH: Reflex at diagnosis - ALKfus

FISH: Reflex at diagnosis - ALKfus	Overall	
	n	% (N = 15)
No	8	53%
On request	2	13%
Yes	5	33%
NA.	0	-

FISH: Reflex at diagnosis - ROS1fus

FISH: Reflex at diagnosis - ROS1fus	Overall	
	n	% (N = 15)
No	8	53%
On request	2	13%
Yes	5	33%
NA.	0	-

FISH: Reflex at diagnosis - METamp

FISH: Reflex at diagnosis - METamp	Overall	
	n	% (N = 15)
No	11	73%
On request	3	20%

Yes	1	7%
NA.	0	-

FISH: Reflex at diagnosis - HER2amp

FISH: Reflex at diagnosis - HER2amp	Overall	
	n	% (N = 15)
No	12	80%
On request	2	13%
Yes	1	7%
NA.	0	-

FISH: Reflex at diagnosis - RETfus

FISH: Reflex at diagnosis - RETfus	Overall	
	n	% (N = 15)
No	10	67%
On request	3	20%
Yes	2	13%
NA.	0	-

FISH: Reflex at diagnosis - NTRKfus

FISH: Reflex at diagnosis - NTRKfus	Overall	
	n	% (N = 15)
No	12	80%
On request	3	20%
NA.	0	-

FISH: Testing at progression / relapse / other post Dx timepoints - ALKfus

FISH: Testing at progression / relapse / other post Dx timepoints - ALKfus	Overall	
	n	% (N = 15)
No	10	67%
On request	3	20%
Yes	2	13%
NA.	0	-

FISH: Testing at progression / relapse / other post Dx timepoints ROS1fus

FISH: Testing at progression / relapse / other post Dx timepoints ROS1fus	Overall	
	n	% (N = 15)
No	10	67%
On request	3	20%
Yes	2	13%
NA.	0	-

FISH: Testing at progression / relapse / other post Dx timepoints - METamp

FISH: Testing at progression / relapse / other post Dx timepoints - METamp	Overall	
	n	% (N = 15)
No	12	80%
On request	3	20%
NA.	0	-

FISH: Testing at progression / relapse / other post Dx timepoints - HER2amp

FISH: Testing at progression / relapse / other post Dx timepoints - HER2amp	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

FISH: Testing at progression / relapse / other post Dx timepoints - RETfus

FISH: Testing at progression / relapse / other post Dx timepoints - RETfus	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

FISH: Testing at progression / relapse / other post Dx timepoints - NTRKfus

FISH: Testing at progression / relapse / other post Dx timepoints - NTRKfus	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

FISH: Performed by pathology lab - ALKfus

FISH: Performed by pathology lab - ALKfus	Overall	
	n	% (N = 8)
No	3	38%
Yes	5	62%
NA.	7	-

FISH: Performed by pathology lab - ROS1fus

FISH: Performed by pathology lab - ROS1fus	Overall	
	n	% (N = 8)
No	3	38%
Yes	5	62%
NA.	7	-

FISH: Performed by pathology lab - METamp

FISH: Performed by pathology lab - METamp	Overall	
	n	% (N = 5)
No	2	40%
Other external lab	1	20%
Yes	2	40%
NA.	10	-

FISH: Performed by pathology lab - HER2amp

FISH: Performed by pathology lab - HER2amp	Overall	
	n	% (N = 4)
No	2	50%
Yes	2	50%
NA.	11	-

FISH: Performed by pathology lab - RETfus

FISH: Performed by pathology lab - RETfus	Overall	
	n	% (N = 6)
No	2	33%
Other external lab	1	17%
Yes	3	50%
NA.	9	-

FISH: Performed by pathology lab - NTRKfus

FISH: Performed by pathology lab - NTRKfus	Overall	
	n	% (N = 4)
No	2	50%
Yes	2	50%
NA.	11	-

FISH: Moved to GLH / Genomic Centre - ALKfus

FISH: Moved to GLH / Genomic Centre - ALKfus	Overall	
	n	% (N = 8)
No	5	62%
Yes	3	38%
NA.	7	-

FISH: Moved to GLH / Genomic Centre - ROS1fus

FISH: Moved to GLH / Genomic Centre - ROS1fus	Overall	
	n	% (N = 8)
No	5	62%
Yes	3	38%
NA.	7	-

FISH: Moved to GLH / Genomic Centre - METamp

FISH: Moved to GLH / Genomic Centre - METamp	Overall	
	n	% (N = 5)
No	3	60%
Yes	2	40%
NA.	10	-

FISH: Moved to GLH / Genomic Centre - HER2amp

FISH: Moved to GLH / Genomic Centre - HER2amp	Overall	
	n	% (N = 4)
No	2	50%
Yes	2	50%
NA.	11	-

FISH: Moved to GLH / Genomic Centre - RETfus

FISH: Moved to GLH / Genomic Centre - RETfus	Overall	
	n	% (N = 6)
No	4	67%
Yes	2	33%
NA.	9	-

FISH: Moved to GLH / Genomic Centre - NTRKfus

FISH: Moved to GLH / Genomic Centre - NTRKfus	Overall	
	n	% (N = 4)
No	2	50%
Yes	2	50%
NA.	11	-

FISH: Moving to GLH / Genomic hubs - ALKfus

FISH: Moving to GLH / Genomic hubs - ALKfus	Overall	
	n	% (N = 8)

No	8	100%
NA.	7	-

FISH: Moving to GLH / Genomic hubs - ROS1fus

FISH: Moving to GLH / Genomic hubs - ROS1fus	Overall	
	n	% (N = 8)
No	8	100%
NA.	7	-

FISH: Moving to GLH / Genomic hubs - METamp

FISH: Moving to GLH / Genomic hubs - METamp	Overall	
	n	% (N = 5)
No	5	100%
NA.	10	-

FISH: Moving to GLH / Genomic hubs - HER2amp

FISH: Moving to GLH / Genomic hubs - HER2amp	Overall	
	n	% (N = 4)
No	4	100%
NA.	11	-

FISH: Moving to GLH / Genomic hubs - RETfus

FISH: Moving to GLH / Genomic hubs - RETfus	Overall	
	n	% (N = 6)
No	6	100%
NA.	9	-

FISH: Moving to GLH / Genomic hubs - NTRKfus

FISH: Moving to GLH / Genomic hubs - NTRKfus	Overall	
	n	% (N = 4)
No	4	100%
NA.	11	-

FISH: Current average turnaround time - ALKfus

FISH: Current average turnaround time - ALKfus	Overall
	N = 15
Mean	8.4
SD	5.8
Median	7.2
IQR	5.5 to 10
Range	2 to 21
NA.	7

FISH: Current average turnaround time - ROS1fus

FISH: Current average turnaround time - ROS1fus	Overall
	N = 15
Mean	8.4
SD	5.8
Median	7.2
IQR	5.5 to 10
Range	2 to 21
NA.	7

FISH: Current average turnaround time - METamp

FISH: Current average turnaround time - METamp	Overall
	N = 15
Mean	14.1
SD	11.3
Median	10
IQR	7.5 to 21
Range	2 to 30
NA.	10

FISH: Current average turnaround time - HER2amp

FISH: Current average turnaround time - HER2amp	Overall
	N = 15
Mean	10.1
SD	8
Median	8.8
IQR	6.1 to 12.8
Range	2 to 21
NA.	11

FISH: Current average turnaround time - RETfus

FISH: Current average turnaround time - RETfus	Overall
	N = 15
Mean	12.4
SD	10.9
Median	8.8
IQR	4.9 to 18.2
Range	2 to 30
NA.	9

FISH: Current average turnaround time - NTRKfus

FISH: Current average turnaround time - NTRKfus	Overall
	N = 15
Mean	9.2
SD	8.5
Median	7
IQR	3.5 to 12.8
Range	2 to 21
NA.	11

RT-PCR: Reflex at diagnosis - EGFR

RT-PCR: Reflex at diagnosis - EGFR	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

RT-PCR: Reflex at diagnosis - ROS1fus

RT-PCR: Reflex at diagnosis - ROS1fus	Overall	
	n	% (N = 15)
No	13	87%
Yes	2	13%
NA.	0	-

RT-PCR: Reflex at diagnosis - ALKfus

RT-PCR: Reflex at diagnosis - ALKfus	Overall	
	n	% (N = 15)
No	13	87%
Yes	2	13%
NA.	0	-

RT-PCR: Reflex at diagnosis - ALK

RT-PCR: Reflex at diagnosis - ALK	Overall	
	n	% (N = 15)
No	13	87%
Yes	2	13%
NA.	0	-

RT-PCR: Reflex at diagnosis - BRAF

RT-PCR: Reflex at diagnosis - BRAF	Overall	
	n	% (N = 15)
No	6	40%
On request	3	20%
Yes	6	40%
NA.	0	-

RT-PCR: Reflex at diagnosis - KRAS

RT-PCR: Reflex at diagnosis - KRAS	Overall	
	n	% (N = 15)
No	8	53%
On request	3	20%
Yes	4	27%

NA.	0	-

RT-PCR: Reflex at diagnosis - METex14

RT-PCR: Reflex at diagnosis - METex14	Overall	
	n	% (N = 15)
No	9	60%
On request	3	20%
Yes	3	20%
NA.	0	-

RT-PCR: Reflex at diagnosis - HER2

RT-PCR: Reflex at diagnosis - HER2	Overall	
	n	% (N = 15)
No	12	80%
On request	2	13%
Yes	1	7%
NA.	0	-

RT-PCR: Reflex at diagnosis - RETfus

RT-PCR: Reflex at diagnosis - RETfus	Overall	
	n	% (N = 15)
No	10	67%
On request	2	13%
Yes	3	20%
NA.	0	-

RT-PCR: Reflex at diagnosis - NTRKfus

RT-PCR: Reflex at diagnosis - NTRKfus	Overall	
	n	% (N = 15)
No	9	60%
On request	4	27%
Yes	2	13%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepoints - EGFR

RT-PCR: Testing at progression / relapse / other post Dx timepoints - EGFR	Overall	
	n	% (N = 15)
No	7	47%
On request	5	33%
Yes	3	20%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepoints - ROS1fus

RT-PCR: Testing at progression / relapse / other post Dx timepoints - ROS1fus	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepointss - ALKfus

RT-PCR: Testing at progression / relapse / other post Dx timepointss - ALKfus	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepoints - ALK

RT-PCR: Testing at progression / relapse / other post Dx timepoints - ALK	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepointss - BRAF

RT-PCR: Testing at progression / relapse / other post Dx timepointss - BRAF	Overall	
	n	% (N = 15)
No	9	60%
On request	5	33%
Yes	1	7%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepoints - KRAS

RT-PCR: Testing at progression / relapse / other post Dx timepoints - KRAS	Overall	
	n	% (N = 15)
No	11	73%
On request	4	27%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepoints - METex14

RT-PCR: Testing at progression / relapse / other post Dx timepoints - METex14	Overall	
	n	% (N = 15)
No	12	80%
On request	3	20%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepoints - HER2

RT-PCR: Testing at progression / relapse / other post Dx timepoints - HER2	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepointss - RETfus

RT-PCR: Testing at progression / relapse / other post Dx timepointss - RETfus	Overall	
	n	% (N = 15)
No	14	93%
On request	1	7%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepoints - NTRKfus

RT-PCR: Testing at progression / relapse / other post Dx timepoints - NTRKfus	Overall	
	n	% (N = 15)
No	12	80%
On request	3	20%
NA.	0	-

RT-PCR: Performed by pathology lab - EGFR

RT-PCR: Performed by pathology lab - EGFR	Overall	
	n	% (N = 11)
No	1	9%
Other external lab	1	9%
Yes	9	82%
NA.	4	-

RT-PCR: Performed by pathology lab - ROS1fus

RT-PCR: Performed by pathology lab - ROS1fus	Overall	
	n	% (N = 2)
Yes	2	100%
NA.	13	-

RT-PCR: Performed by pathology lab - ALKfus

RT-PCR: Performed by pathology lab - ALKfus	Overall	
	n	% (N = 2)
Yes	2	100%
NA.	13	-

RT-PCR: Performed by pathology lab - ALK

RT-PCR: Performed by pathology lab - ALK	Overall	
	n	% (N = 2)
Yes	2	100%
NA.	13	-

RT-PCR: Performed by pathology lab - BRAF...94

RT-PCR: Performed by pathology lab - BRAF...94	Overall	
	n	% (N = 9)
No	1	11%
Other external lab	2	22%
Yes	6	67%
NA.	6	-

RT-PCR: Performed by pathology lab - KRAS

RT-PCR: Performed by pathology lab - KRAS	Overall	
	n	% (N = 7)
No	1	14%
Other external lab	2	29%
Yes	4	57%
NA.	8	-

RT-PCR: Performed by pathology lab - METex14

RT-PCR: Performed by pathology lab - METex14	Overall	
	n	% (N = 6)
No	1	17%
Other external lab	2	33%
Yes	3	50%
NA.	9	-

RT-PCR: Performed by pathology lab - HER2

RT-PCR: Performed by pathology lab - HER2	Overall	
	n	% (N = 3)
Other external lab	1	33%
Yes	2	67%
NA.	12	-

RT-PCR: Performed by pathology lab - RETfus

RT-PCR: Performed by pathology lab - RETfus	Overall	
	n	% (N = 5)
No	1	20%
Other external lab	1	20%
Yes	3	60%
NA.	10	-

RT-PCR: Performed by pathology lab - NTRKfus

RT-PCR: Performed by pathology lab - NTRKfus	Overall	
	n	% (N = 6)
No	1	17%
Other external lab	2	33%
Yes	3	50%
NA.	9	-

RT-PCR: Moved to GLH / Genomic Centre - EGFR

RT-PCR: Moved to GLH / Genomic Centre - EGFR	Overall	
	n	% (N = 11)
No	10	91%
Yes	1	9%
NA.	4	-

RT-PCR: Moved to GLH / Genomic Centre - ROS1fus

RT-PCR: Moved to GLH / Genomic Centre - ROS1fus	Overall	
	n	% (N = 2)

No	2	100%
NA.	13	-

RT-PCR: Moved to GLH / Genomic Centre - ALKfus

RT-PCR: Moved to GLH / Genomic Centre - ALKfus	Overall	
	n	% (N = 2)
No	2	100%
NA.	13	-

RT-PCR: Moved to GLH / Genomic Centre - ALK

RT-PCR: Moved to GLH / Genomic Centre - ALK	Overall	
	n	% (N = 2)
No	2	100%
NA.	13	-

RT-PCR: Moved to GLH / Genomic Centre - BRAF

RT-PCR: Moved to GLH / Genomic Centre - BRAF	Overall	
	n	% (N = 9)
No	8	89%
Yes	1	11%
NA.	6	-

RT-PCR: Moved to GLH / Genomic Centre - KRAS

RT-PCR: Moved to GLH / Genomic Centre - KRAS	Overall	
	n	% (N = 7)
No	6	86%
Yes	1	14%
NA.	8	-

RT-PCR: Moved to GLH / Genomic Centre - METex14

RT-PCR: Moved to GLH / Genomic Centre - METex14	Overall	
	n	% (N = 6)
No	5	83%
Yes	1	17%
NA.	9	-

RT-PCR: Moved to GLH / Genomic Centre - HER2

RT-PCR: Moved to GLH / Genomic Centre - HER2	Overall	
	n	% (N = 3)
No	3	100%
NA.	12	-

RT-PCR: Moved to GLH / Genomic Centre - RETfus

RT-PCR: Moved to GLH / Genomic Centre - RETfus	Overall	
	n	% (N = 5)
No	4	80%
Yes	1	20%
NA.	10	-

RT-PCR: Moved to GLH / Genomic Centre - NTRKfus

RT-PCR: Moved to GLH / Genomic Centre - NTRKfus	Overall	
	n	% (N = 6)
No	5	83%
Yes	1	17%
NA.	9	-

RT-PCR: Moving to GLH / Genomic hubs - EGFR

RT-PCR: Moving to GLH / Genomic hubs - EGFR	Overall	
	n	% (N = 11)
No	11	100%
NA.	4	-

RT-PCR: Moving to GLH / Genomic hubs - ROS1fus

RT-PCR: Moving to GLH / Genomic hubs - ROS1fus	Overall	
	n	% (N = 2)
No	2	100%
NA.	13	-

RT-PCR: Moving to GLH / Genomic hubs - ALKfus

RT-PCR: Moving to GLH / Genomic hubs - ALKfus	Overall	
	n	% (N = 2)
No	2	100%
NA.	13	-

RT-PCR: Moving to GLH / Genomic hubs - ALK

RT-PCR: Moving to GLH / Genomic hubs - ALK	Overall	
	n	% (N = 2)
No	2	100%
NA.	13	-

RT-PCR: Moving to GLH / Genomic hubs - BRAF

RT-PCR: Moving to GLH / Genomic hubs - BRAF	Overall	
	n	% (N = 9)
No	9	100%
NA.	6	-

RT-PCR: Moving to GLH / Genomic hubs - KRAS

RT-PCR: Moving to GLH / Genomic hubs - KRAS	Overall	
	n	% (N = 7)
No	7	100%
NA.	8	-

RT-PCR: Moving to GLH / Genomic hubs - METex14

RT-PCR: Moving to GLH / Genomic hubs - METex14	Overall	
	n	% (N = 6)
No	6	100%
NA.	9	-

RT-PCR: Moving to GLH / Genomic hubs - HER2

RT-PCR: Moving to GLH / Genomic hubs - HER2	Overall	
	n	% (N = 3)
No	3	100%
NA.	12	-

RT-PCR: Moving to GLH / Genomic hubs - RETfus

RT-PCR: Moving to GLH / Genomic hubs - RETfus	Overall	
	n	% (N = 5)
No	5	100%
NA.	10	-

RT-PCR: Moving to GLH / Genomic hubs - NTRKfus

RT-PCR: Moving to GLH / Genomic hubs - NTRKfus	Overall	

	n	% (N = 6)
No	6	100%
NA.	9	-

RT-PCR: Current average turnaround time - EGFR

RT-PCR: Current average turnaround time - EGFR	Overall
	N = 15
Mean	7.5
SD	8.4
Median	6
IQR	2 to 7.2
Range	1 to 30
NA.	4

RT-PCR: Current average turnaround times - ROS1fus

RT-PCR: Current average turnaround times - ROS1fus	Overall
	N = 15
Mean	4.8
SD	3.9
Median	4.8
IQR	3.4 to 6.1
Range	2 to 7.5
NA.	13

RT-PCR: Current average turnaround time - ALKfus

RT-PCR: Current average turnaround time - ALKfus	Overall
	N = 15
Mean	4.8
SD	3.9
Median	4.8
IQR	3.4 to 6.1
Range	2 to 7.5
NA.	13

RT-PCR: Current average turnaround time - ALK

RT-PCR: Current average turnaround time - ALK	Overall
	N = 15
Mean	4.8
SD	3.9
Median	4.8
IQR	3.4 to 6.1
Range	2 to 7.5
NA.	13

RT-PCR: Current average turnaround time - BRAF

RT-PCR: Current average turnaround time - BRAF	Overall
	N = 15
Mean	10.6
SD	11.2
Median	7
IQR	2 to 14
Range	1 to 30
NA.	6

RT-PCR: Current average turnaround time - KRAS

RT-PCR: Current average turnaround time - KRAS	Overall
	N = 15
Mean	12.4
SD	12.2
Median	7.5
IQR	3 to 21
Range	1 to 30
NA.	8

RT-PCR: Current average turnaround time - METex14

RT-PCR: Current average turnaround time - METex14	Overall
	N = 15
Mean	14.2
SD	12.1
Median	10.8
IQR	4.9 to 24.5

Range	2 to 30
NA.	9

RT-PCR: Current average turnaround time - HER2

RT-PCR: Current average turnaround time - HER2	Overall
	N = 15
Mean	13.8
SD	14.1
Median	7.5
IQR	5.8 to 18.8
Range	4 to 30
NA.	12

RT-PCR: Current average turnaround time - RETfus

RT-PCR: Current average turnaround time - RETfus	Overall
	N = 15
Mean	11.1
SD	10.5
Median	7.5
IQR	4 to 14
Range	2 to 28
NA.	10

RT-PCR: Current average turnaround time - NTRKfus

RT-PCR: Current average turnaround time - NTRKfus	Overall
	N = 15
Mean	11.1
SD	10.5
Median	7.5
IQR	4 to 14
Range	2 to 28
NA.	10

NGS: Reflex at diagnosis - EGFR

NGS: Reflex at diagnosis - EGFR	Overall	
	n	% (N = 15)

No	3	20%
On request	3	20%
Yes	9	60%
NA.	0	-

NGS: Reflex at diagnosis - ROS1fus

NGS: Reflex at diagnosis - ROS1fus	Overall	
	n	% (N = 15)
No	5	33%
On request	3	20%
Yes	7	47%
NA.	0	-

NGS: Reflex at diagnosis - ALKfus

NGS: Reflex at diagnosis - ALKfus	Overall	
	n	% (N = 15)
No	4	27%
On request	3	20%
Yes	8	53%
NA.	0	-

NGS: Reflex at diagnosis - BRAF

NGS: Reflex at diagnosis - BRAF	Overall	
	n	% (N = 15)
No	3	20%
On request	3	20%
Yes	9	60%
NA.	0	-

NGS: Reflex at diagnosis - KRAS

NGS: Reflex at diagnosis - KRAS	Overall	
	n	% (N = 15)
No	3	20%
On request	3	20%
Yes	9	60%
NA.	0	-

NGS: Reflex at diagnosis - METex14

NGS: Reflex at diagnosis - METex14	Overall	
	n	% (N = 15)
No	4	27%
On request	3	20%
Yes	8	53%
NA.	0	-

NGS: Reflex at diagnosis - HER2

NGS: Reflex at diagnosis - HER2	Overall	
	n	% (N = 15)
No	7	47%
On request	3	20%
Yes	5	33%
NA.	0	-

NGS: Reflex at diagnosis - RETfus

NGS: Reflex at diagnosis - RETfus	Overall	
	n	% (N = 15)
No	4	27%
On request	3	20%
Yes	8	53%
NA.	0	-

NGS: Reflex at diagnosis - NTRKfus

NGS: Reflex at diagnosis - NTRKfus	Overall	
	n	% (N = 15)
No	5	33%
On request	3	20%
Yes	7	47%
NA.	0	-

NGS: Testing at progression / relapse / other post Dx timepoints - EGFR

NGS: Testing at progression / relapse / other post Dx timepoints - EGFR	Overall	

	n	% (N = 15)
No	7	47%
On request	8	53%
NA.	0	-

NGS: Testing at progression / relapse / other post
Dx timepoints - ROS1fus

NGS: Testing at progression / relapse / other post Dx timepoints - ROS1fus	Overall	
	n	% (N = 15)
No	8	53%
On request	7	47%
NA.	0	-

NGS: Testing at progression / relapse / other post
Dx timepointss - ALKfus

NGS: Testing at progression / relapse / other post Dx timepointss - ALKfus	Overall	
	n	% (N = 15)
No	8	53%
On request	7	47%
NA.	0	-

NGS: Testing at progression / relapse / other post
Dx timepointss - BRAF

NGS: Testing at progression / relapse / other post Dx timepointss - BRAF	Overall	
	n	% (N = 15)
No	8	53%
On request	7	47%
NA.	0	-

NGS: Testing at progression / relapse / other post
Dx timepoints - KRAS

NGS: Testing at progression / relapse / other post Dx timepoints - KRAS	Overall	
	n	% (N = 15)
No	8	53%

On request	7	47%
NA.	0	-

NGS: Testing at progression / relapse / other post Dx timepoints - METex14

NGS: Testing at progression / relapse / other post Dx timepoints - METex14	Overall	
	n	% (N = 15)
No	8	53%
On request	7	47%
NA.	0	-

NGS: Testing at progression / relapse / other post Dx timepoints - HER2

NGS: Testing at progression / relapse / other post Dx timepoints - HER2	Overall	
	n	% (N = 15)
No	9	60%
On request	6	40%
NA.	0	-

NGS: Testing at progression / relapse / other post Dx timepointss - RETfus

NGS: Testing at progression / relapse / other post Dx timepointss - RETfus	Overall	
	n	% (N = 15)
No	8	53%
On request	7	47%
NA.	0	-

NGS: Testing at progression / relapse / other post Dx timepoints - NTRKfus

NGS: Testing at progression / relapse / other post Dx timepoints - NTRKfus	Overall	
	n	% (N = 15)
No	8	53%
On request	7	47%
NA.	0	-

NGS: Performed by pathology lab - EGFR

NGS: Performed by pathology lab - EGFR	Overall	
	n	% (N = 12)
No	10	83%
Yes	2	17%
NA.	3	-

NGS: Performed by pathology lab - ROS1fus

NGS: Performed by pathology lab - ROS1fus	Overall	
	n	% (N = 10)
No	10	100%
NA.	5	-

NGS: Performed by pathology lab - ALKfus

NGS: Performed by pathology lab - ALKfus	Overall	
	n	% (N = 11)
No	11	100%
NA.	4	-

RT-PCR: Performed by pathology lab - BRAF...151

RT-PCR: Performed by pathology lab - BRAF...151	Overall	
	n	% (N = 12)
No	11	92%
Yes	1	8%
NA.	3	-

NGS: Performed by pathology lab - KRAS

NGS: Performed by pathology lab - KRAS	Overall	
	n	% (N = 12)
No	11	92%
Yes	1	8%
NA.	3	-

NGS: Performed by pathology lab - METex14

NGS: Performed by pathology lab - METex14	Overall	
	n	% (N = 11)
No	10	91%
Yes	1	9%
NA.	4	-

NGS: Performed by pathology lab - HER2

NGS: Performed by pathology lab - HER2	Overall	
	n	% (N = 8)
No	8	100%
NA.	7	-

NGS: Performed by pathology lab - RETfus

NGS: Performed by pathology lab - RETfus	Overall	
	n	% (N = 11)
No	11	100%
NA.	4	-

NGS: Performed by pathology lab - NTRKfus

NGS: Performed by pathology lab - NTRKfus	Overall	
	n	% (N = 10)
No	10	100%
NA.	5	-

NGS: Moved to GLH / Genomic Centre - EGFR

NGS: Moved to GLH / Genomic Centre - EGFR	Overall	
	n	% (N = 12)
No	2	17%
Yes	10	83%
NA.	3	-

NGS: Moved to GLH / Genomic Centre - ROS1fus

NGS: Moved to GLH / Genomic Centre - ROS1fus	Overall	
	n	% (N = 10)
Yes	10	100%
NA.	5	-

NGS: Moved to GLH / Genomic Centre - ALKfus

NGS: Moved to GLH / Genomic Centre - ALKfus	Overall	
	n	% (N = 11)
Yes	11	100%
NA.	4	-

NGS: Moved to GLH / Genomic Centre - BRAF

NGS: Moved to GLH / Genomic Centre - BRAF	Overall	
	n	% (N = 12)
No	1	8%
Yes	11	92%
NA.	3	-

NGS: Moved to GLH / Genomic Centre - KRAS

NGS: Moved to GLH / Genomic Centre - KRAS	Overall	
	n	% (N = 12)
No	1	8%
Yes	11	92%
NA.	3	-

NGS: Moved to GLH / Genomic Centre - METex14

NGS: Moved to GLH / Genomic Centre - METex14	Overall	
	n	% (N = 11)
No	1	9%
Yes	10	91%

NA.	4	-

NGS: Moved to GLH / Genomic Centre - HER2

NGS: Moved to GLH / Genomic Centre - HER2	Overall	
	n	% (N = 8)
Yes	8	100%
NA.	7	-

NGS: Moved to GLH / Genomic Centre - RETfus

NGS: Moved to GLH / Genomic Centre - RETfus	Overall	
	n	% (N = 11)
Yes	11	100%
NA.	4	-

NGS: Moved to GLH / Genomic Centre - NTRKfus

NGS: Moved to GLH / Genomic Centre - NTRKfus	Overall	
	n	% (N = 10)
Yes	10	100%
NA.	5	-

NGS: Moving to GLH / Genomic hubs - EGFR

NGS: Moving to GLH / Genomic hubs - EGFR	Overall	
	n	% (N = 12)
No	12	100%
NA.	3	-

NGS: Moving to GLH / Genomic hubs - ROS1fus

NGS: Moving to GLH / Genomic hubs - ROS1fus	Overall	
	n	% (N = 10)

No	10	100%
NA.	5	-

NGS: Moving to GLH / Genomic hubs - ALKfus

NGS: Moving to GLH / Genomic hubs - ALKfus	Overall	
	n	% (N = 11)
No	11	100%
NA.	4	-

NGS: Moving to GLH / Genomic hubs - BRAF

NGS: Moving to GLH / Genomic hubs - BRAF	Overall	
	n	% (N = 12)
No	12	100%
NA.	3	-

NGS: Moving to GLH / Genomic hubs - KRAS

NGS: Moving to GLH / Genomic hubs - KRAS	Overall	
	n	% (N = 12)
No	12	100%
NA.	3	-

NGS: Moving to GLH / Genomic hubs - METex14

NGS: Moving to GLH / Genomic hubs - METex14	Overall	
	n	% (N = 11)
No	11	100%
NA.	4	-

NGS: Moving to GLH / Genomic hubs - HER2

NGS: Moving to GLH / Genomic hubs - HER2	Overall	
	n	% (N = 8)
No	8	100%
NA.	7	-

NGS: Moving to GLH / Genomic hubs - RETfus

NGS: Moving to GLH / Genomic hubs - RETfus	Overall	
	n	% (N = 11)
No	11	100%
NA.	4	-

NGS: Moving to GLH / Genomic hubs - NTRKfus

NGS: Moving to GLH / Genomic hubs - NTRKfus	Overall	
	n	% (N = 10)
No	10	100%
NA.	5	-

NGS: Current average turnaround time - EGFR

NGS: Current average turnaround time - EGFR	Overall
	N = 15
Mean	16.9
SD	6
Median	17.5
IQR	13 to 21.8
Range	7.5 to 24.5
NA.	4

NGS: Current average turnaround times - ROS1fus

NGS: Current average turnaround times - ROS1fus	Overall
	N = 15
Mean	19.2
SD	5.6
Median	19
IQR	14 to 24.5
Range	10 to 24.5
NA.	6

NGS: Current average turnaround time - ALKfus

NGS: Current average turnaround time - ALKfus	Overall
	N = 15
Mean	18.5
SD	5.8
Median	18.5
IQR	14 to 24.5
Range	10 to 24.5
NA.	5

NGS: Current average turnaround time - BRAF

NGS: Current average turnaround time - BRAF	Overall
	N = 15
Mean	16.9
SD	6
Median	17.5
IQR	13 to 21.8
Range	7.5 to 24.5
NA.	4

NGS: Current average turnaround time - KRAS

NGS: Current average turnaround time - KRAS	Overall
	N = 15
Mean	16.9
SD	6
Median	17.5
IQR	13 to 21.8
Range	7.5 to 24.5
NA.	4

NGS: Current average turnaround time - METex14

NGS: Current average turnaround time - METex14	Overall
	N = 15
Mean	17.4
SD	6.1
Median	17.8
IQR	14 to 23.1
Range	7.5 to 24.5
NA.	5

NGS: Current average turnaround time - HER2

NGS: Current average turnaround time - HER2	Overall
	N = 15
Mean	17.5
SD	5.5
Median	17.5
IQR	14 to 21.2
Range	10 to 24.5
NA.	8

NGS: Current average turnaround time - RETfus

NGS: Current average turnaround time - RETfus	Overall
	N = 15
Mean	18.5
SD	5.8
Median	18.5
IQR	14 to 24.5
Range	10 to 24.5
NA.	5

NGS: Current average turnaround time - NTRKfus

NGS: Current average turnaround time - NTRKfus	Overall
	N = 15
Mean	19.2
SD	5.6
Median	19
IQR	14 to 24.5
Range	10 to 24.5
NA.	6

Others

Others	Overall	
	n	% (N = 15)
N/A	14	93%
PIK3CA, TP53	1	7%
NA.	0	-

Reflex at diagnosis : Others - PIK3CA

Reflex at diagnosis : Others - PIK3CA	Overall	
	n	% (N = 15)
N/A	14	93%
Yes	1	7%
NA.	0	-

Testing at progression/ relapse/ other post Dx timepoints: Others - PIK3CA

Testing at progression/ relapse/ other post Dx timepoints: Others - PIK3CA	Overall	
	n	% (N = 15)
N/A	14	93%
No	1	7%
NA.	0	-

Performed by pathology lab: Others - PIK3CA

Performed by pathology lab: Others - PIK3CA	Overall	
	n	% (N = 15)
N/A	14	93%
No	1	7%
NA.	0	-

Moved to GLH/ Genomic centre: Others - PIK3CA

Moved to GLH/ Genomic centre: Others - PIK3CA	Overall	
	n	% (N = 15)
N/A	14	93%
Yes	1	7%
NA.	0	-

Moving to GLH/ Genomic hub: Others - PIK3CA

Moving to GLH/ Genomic hub: Others - PIK3CA	Overall	
	n	% (N = 15)

N/A	14	93%
No	1	7%
NA.	0	-

Current Average Turnaround time - PIK3CA

Current Average Turnaround time - PIK3CA	Overall	
	n	% (N = 15)
10 to 14	1	7%
N/A	14	93%
NA.	0	-

Reflex at diagnosis : Others - TP53

Reflex at diagnosis : Others - TP53	Overall	
	n	% (N = 15)
N/A	14	93%
Yes	1	7%
NA.	0	-

Testing at progression/ relapse/ other post Dx timepoints: Others - TP53

Testing at progression/ relapse/ other post Dx timepoints: Others - TP53	Overall	
	n	% (N = 15)
N/A	14	93%
No	1	7%
NA.	0	-

Performed by pathology lab: Others - TP53

Performed by pathology lab: Others - TP53	Overall	
	n	% (N = 15)
N/A	14	93%
No	1	7%
NA.	0	-

Moved to GLH/ Genomic centre: Others - TP53

Moved to GLH/ Genomic centre: Others - TP53	Overall	
	n	% (N = 15)
N/A	14	93%
Yes	1	7%
NA.	0	-

Moving to GLH/ Genomic hub: Others - TP53

Moving to GLH/ Genomic hub: Others - TP53	Overall	
	n	% (N = 15)
N/A	14	93%
No	1	7%
NA.	0	-

Current Average Turnaround time - TP53

Current Average Turnaround time - TP53	Overall	
	n	% (N = 15)
10 to 14	1	7%
N/A	14	93%
NA.	0	-

IHC: Reflex at diagnosis - BRAF

IHC: Reflex at diagnosis - BRAF	Overall	
	n	% (N = 11)
No	8	73%
On request	3	27%
NA.	0	-

IHC: Reflex at diagnosis - PD-L1

IHC: Reflex at diagnosis - PD-L1	Overall	
	n	% (N = 11)
No	9	82%
On request	2	18%
NA.	0	-

IHC: Testing at progression / relapse / other post Dx timepoints - BRAF

IHC: Testing at progression / relapse / other post Dx timepoints - BRAF	Overall	
	n	% (N = 11)
No	9	82%
On request	2	18%
NA.	0	-

IHC: Testing at progression / relapse / other post Dx timepoints - PD-L1

IHC: Testing at progression / relapse / other post Dx timepoints - PD-L1	Overall	
	n	% (N = 11)
No	9	82%
On request	2	18%
NA.	0	-

IHC: Performed by pathology lab - BRAF

IHC: Performed by pathology lab - BRAF	Overall	
	n	% (N = 3)
Other external lab	2	67%

Yes	1	33%
NA.	8	-

IHC: Performed by pathology lab - PD-L1

IHC: Performed by pathology lab - PD-L1	Overall	
	n	% (N = 2)
Other external lab	1	50%
Yes	1	50%
NA.	9	-

IHC: Moved to GLH / Genomic Centre - BRAF

IHC: Moved to GLH / Genomic Centre - BRAF	Overall	
	n	% (N = 3)
No	3	100%
NA.	8	-

IHC: Moved to GLH / Genomic Centre - PD-L1

IHC: Moved to GLH / Genomic Centre - PD-L1	Overall	
	n	% (N = 2)
No	2	100%
NA.	9	-

IHC: Moving to GLH / Genomic hubs - BRAF

IHC: Moving to GLH / Genomic hubs - BRAF	Overall	
	n	% (N = 3)
No	3	100%
NA.	8	-

IHC: Moving to GLH / Genomic hubs - PD-L1

IHC: Moving to GLH / Genomic hubs - PD-L1	Overall	
	n	% (N = 2)
No	2	100%
NA.	9	-

IHC: Current average turnaround time - BRAF

IHC: Current average turnaround time - BRAF	Overall
	N = 11
Mean	13
SD	14.9
Median	7
IQR	4.5 to 18.5
Range	2 to 30
NA.	8

IHC: Current average turnaround time - PD-L1

IHC: Current average turnaround time - PD-L1	Overall
	N = 11
Mean	17
SD	18.4
Median	17
IQR	10.5 to 23.5
Range	4 to 30
NA.	9

Sanger Sequencing: Reflex at diagnosis - BRAF

Sanger Sequencing: Reflex at diagnosis - BRAF	Overall	
	n	% (N = 11)
No	10	91%
On request	1	9%
NA.	0	-

Sanger Sequencing: Reflex at diagnosis - NRAS

Sanger Sequencing: Reflex at diagnosis - NRAS	Overall	
	n	% (N = 11)
No	11	100%
NA.	0	-

Sanger Sequencing: Testing at progression / relapse / other post Dx timepoints - BRAF

Sanger Sequencing: Testing at progression / relapse / other post Dx timepoints - BRAF	Overall	
	n	% (N = 11)

No	10	91%
On request	1	9%
NA.	0	-

Sanger Sequencing: Testing at progression / relapse / other post Dx timepoints - NRAS

Sanger Sequencing: Testing at progression / relapse / other post Dx timepoints - NRAS	Overall	
	n	% (N = 11)
No	11	100%
NA.	0	-

Sanger Sequencing: Performed by pathology lab - BRAF

Sanger Sequencing: Performed by pathology lab - BRAF	Overall	
	n	% (N = 1)
Other external lab	1	100%
NA.	10	-

Sanger Sequencing: Moved to GLH / Genomic Centre - BRAF

Sanger Sequencing: Moved to GLH / Genomic Centre - BRAF	Overall	
	n	% (N = 1)
No	1	100%
NA.	10	-

Sanger Sequencing: Moving to GLH / Genomic hubs - BRAF

Sanger Sequencing: Moving to GLH / Genomic hubs - BRAF	Overall	
	n	% (N = 1)
No	1	100%
NA.	10	-

Sanger Sequencing: Current average turnaround time - BRAF

Sanger Sequencing: Current average turnaround time - BRAF	Overall	
	n	% (N = 1)
7	1	100%
NA.	10	-

Pyrosequencing: Reflex at diagnosis - BRAF

Pyrosequencing: Reflex at diagnosis - BRAF	Overall	
	n	% (N = 11)
No	11	100%
NA.	0	-

Pyrosequencing: Testing at progression / relapse / other post Dx timepoints - BRAF

Pyrosequencing: Testing at progression / relapse / other post Dx timepoints - BRAF	Overall	
	n	% (N = 11)
No	11	100%
NA.	0	-

RT-PCR: Reflex at diagnosis - BRAF

RT-PCR: Reflex at diagnosis - BRAF	Overall	
	n	% (N = 11)
No	2	18%
On request	1	9%
Yes	8	73%
NA.	0	-

RT-PCR: Reflex at diagnosis - NRAS

RT-PCR: Reflex at diagnosis - NRAS	Overall	
	n	% (N = 11)
No	8	73%
On request	2	18%
Yes	1	9%
NA.	0	-

RT-PCR: Reflex at diagnosis - KIT

RT-PCR: Reflex at diagnosis - KIT	Overall	
	n	% (N = 11)
No	9	82%
On request	2	18%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepointss - BRAF

RT-PCR: Testing at progression / relapse / other post Dx timepointss - BRAF	Overall	
	n	% (N = 11)
No	7	64%
On request	2	18%
Yes	2	18%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepointss - NRAS

RT-PCR: Testing at progression / relapse / other post Dx timepointss - NRAS	Overall	
	n	% (N = 11)
No	9	82%
On request	1	9%
Yes	1	9%
NA.	0	-

RT-PCR: Testing at progression / relapse / other post Dx timepointss - KIT

RT-PCR: Testing at progression / relapse / other post Dx timepointss - KIT	Overall	
	n	% (N = 11)
No	10	91%
On request	1	9%
NA.	0	-

RT-PCR: Performed by pathology lab - BRAF

RT-PCR: Performed by pathology lab - BRAF	Overall	
	n	% (N = 9)
No	1	11%
Other external lab	2	22%
Yes	6	67%
NA.	2	-

RT-PCR: Performed by pathology lab - NRAS

RT-PCR: Performed by pathology lab - NRAS	Overall	
	n	% (N = 2)
Other external lab	1	50%
Yes	1	50%
NA.	9	-

RT-PCR: Performed by pathology lab - KIT

RT-PCR: Performed by pathology lab - KIT	Overall	
	n	% (N = 1)
Other external lab	1	100%
NA.	10	-

RT-PCR: Moved to GLH / Genomic Centre - BRAF

RT-PCR: Moved to GLH / Genomic Centre - BRAF	Overall	
	n	% (N = 9)
No	8	89%
Yes	1	11%
NA.	2	-

RT-PCR: Moved to GLH / Genomic Centre - NRAS

RT-PCR: Moved to GLH / Genomic Centre - NRAS	Overall	
	n	% (N = 3)
No	3	100%
NA.	8	-

RT-PCR: Moved to GLH / Genomic Centre - KIT

RT-PCR: Moved to GLH / Genomic Centre - KIT	Overall	
	n	% (N = 2)
No	2	100%
NA.	9	-

RT-PCR: Moving to GLH / Genomic hubs - BRAF

RT-PCR: Moving to GLH / Genomic hubs - BRAF	Overall	
	n	% (N = 9)
No	9	100%
NA.	2	-

RT-PCR: Moving to GLH / Genomic hubs - NRAS

RT-PCR: Moving to GLH / Genomic hubs - NRAS	Overall	
	n	% (N = 3)
No	3	100%
NA.	8	-

RT-PCR: Moving to GLH / Genomic hubs - KIT

RT-PCR: Moving to GLH / Genomic hubs - KIT	Overall	
	n	% (N = 2)
No	2	100%
NA.	9	-

RT-PCR: Current average turnaround time - BRAF

RT-PCR: Current average turnaround time - BRAF	Overall
	N = 11
Mean	7.5
SD	8.9
Median	6
IQR	2.5 to 7.5
Range	1 to 30
NA.	2

RT-PCR: Current average turnaround time - NRAS

RT-PCR: Current average turnaround time - NRAS	Overall
	N = 11
Mean	17.8
SD	21
Median	7.5
IQR	5.8 to 24.8
Range	4 to 42
NA.	8

RT-PCR: Current average turnaround time - KIT

RT-PCR: Current average turnaround time - KIT	Overall
	N = 11
Mean	23
SD	26.9
Median	23
IQR	13.5 to 32.5
Range	4 to 42
NA.	9

NGS: Reflex at diagnosis - BRAF

NGS: Reflex at diagnosis - BRAF	Overall	
	n	% (N = 11)
No	4	36%
On request	5	45%
Yes	2	18%
NA.	0	-

NGS: Reflex at diagnosis - NRAS

NGS: Reflex at diagnosis - NRAS	Overall	
	n	% (N = 11)
No	3	27%
On request	6	55%
Yes	2	18%
NA.	0	-

NGS: Reflex at diagnosis - KIT

NGS: Reflex at diagnosis - KIT	Overall	
	n	% (N = 11)
No	3	27%
On request	6	55%

Yes	2	18%
NA.	0	-

NGS: Testing at progression / relapse / other post Dx timepointss - BRAF

NGS: Testing at progression / relapse / other post Dx timepointss - BRAF	Overall	
	n	% (N = 11)
No	9	82%
On request	2	18%
NA.	0	-

NGS: Testing at progression / relapse / other post Dx timepointss - NRAS

NGS: Testing at progression / relapse / other post Dx timepointss - NRAS	Overall	
	n	% (N = 11)
No	9	82%
On request	2	18%
NA.	0	-

NGS: Testing at progression / relapse / other post Dx timepointss - KIT

NGS: Testing at progression / relapse / other post Dx timepointss - KIT	Overall	
	n	% (N = 11)
No	9	82%
On request	2	18%
NA.	0	-

NGS: Performed by pathology lab - BRAF

NGS: Performed by pathology lab - BRAF	Overall	
	n	% (N = 7)
No	6	86%
Yes	1	14%
NA.	4	-

NGS: Performed by pathology lab - NRAS

NGS: Performed by pathology lab - NRAS	Overall	
	n	% (N = 8)
No	6	75%
Other external lab	1	12%
Yes	1	12%
NA.	3	-

NGS: Performed by pathology lab - KIT

NGS: Performed by pathology lab - KIT	Overall	
	n	% (N = 8)
No	6	75%
Other external lab	1	12%
Yes	1	12%
NA.	3	-

NGS: Moved to GLH / Genomic Centre - BRAF

NGS: Moved to GLH / Genomic Centre - BRAF	Overall	
	n	% (N = 7)
No	2	29%
Yes	5	71%
NA.	4	-

NGS: Moved to GLH / Genomic Centre - NRAS

NGS: Moved to GLH / Genomic Centre - NRAS	Overall	
	n	% (N = 8)
No	3	38%
Yes	5	62%
NA.	3	-

NGS: Moved to GLH / Genomic Centre - KIT

NGS: Moved to GLH / Genomic Centre - KIT	Overall	
	n	% (N = 8)
No	3	38%
Yes	5	62%
NA.	3	-

NGS: Moving to GLH / Genomic hubs - BRAF

NGS: Moving to GLH / Genomic hubs - BRAF	Overall	
	n	% (N = 7)
No	6	86%
Yes	1	14%
NA.	4	-

NGS: Moving to GLH / Genomic hubs - NRAS

NGS: Moving to GLH / Genomic hubs - NRAS	Overall	
	n	% (N = 8)
No	7	88%
Yes	1	12%
NA.	3	-

NGS: Moving to GLH / Genomic hubs - KIT

NGS: Moving to GLH / Genomic hubs - KIT	Overall	
	n	% (N = 8)
No	7	88%
Yes	1	12%
NA.	3	-

NGS: Current average turnaround time - BRAF

NGS: Current average turnaround time - BRAF	Overall
	N = 11
Mean	23.2
SD	11.1
Median	21.5
IQR	15.8 to 26.2
Range	12 to 45
NA.	4

NGS: Current average turnaround time - NRAS

NGS: Current average turnaround time - NRAS	Overall
	N = 11
Mean	23.2

SD	11.1
Median	21.5
IQR	15.8 to 26.2
Range	12 to 45
NA.	4

NGS: Current average turnaround time - KIT

NGS: Current average turnaround time - KIT	Overall
	N = 11
Mean	23.2
SD	11.1
Median	21.5
IQR	15.8 to 26.2
Range	12 to 45
NA.	4

Others

Others	Overall	
	n	% (N = 11)
BRAF FISH	1	9%
KIT pyrosequencing	1	9%
N/A	8	73%
NTRK1-3	1	9%
NA.	0	-

Reflex at diagnosis - NTRK1-3

Reflex at diagnosis - NTRK1-3	Overall	
	n	% (N = 11)
N/A	10	91%
On request	1	9%
NA.	0	-

Testing at progression/ relapse/ other post Dx timepoints - NTRK1-3

Testing at progression/ relapse/ other post Dx timepoints - NTRK1-3	Overall	
	n	% (N = 11)
N/A	10	91%
On request	1	9%
NA.	0	-

Performed by pathology lab - NTRK1-3

Performed by pathology lab - NTRK1-3	Overall	
	n	% (N = 11)
N/A	10	91%
No	1	9%
NA.	0	-

Moved to GLH/ Genomic centre - NTRK1-3

Moved to GLH/ Genomic centre - NTRK1-3	Overall	
	n	% (N = 11)
N/A	10	91%
Yes	1	9%
NA.	0	-

Moving to GLH/ Genomic hubs - NTRK1-3

Moving to GLH/ Genomic hubs - NTRK1-3	Overall	
	n	% (N = 11)
N/A	10	91%
No	1	9%
NA.	0	-

Current Average Turnaround time (calendar days) - NTRK1-3

Current Average Turnaround time (calendar days) - NTRK1-3	Overall	
	n	% (N = 11)
21 to 28	1	9%
N/A	10	91%
NA.	0	-

Reflex at diagnosis - KIT pyrosequencing

Reflex at diagnosis - KIT pyrosequencing	Overall	
	n	% (N = 11)
N/A	10	91%

No	1	9%
NA.	0	-

Testing at progression/ relapse/ other post Dx timepoints - KIT pyrosequencing

Testing at progression/ relapse/ other post Dx timepoints - KIT pyrosequencing	Overall	
	n	% (N = 11)
N/A	10	91%
No	1	9%
NA.	0	-

Performed by pathology lab - KIT pyrosequencing

Performed by pathology lab - KIT pyrosequencing	Overall	
	n	% (N = 11)
N/A	10	91%
Yes	1	9%
NA.	0	-

Moved to GLH/ Genomic centre - KIT pyrosequencing

Moved to GLH/ Genomic centre - KIT pyrosequencing	Overall	
	n	% (N = 11)
N/A	10	91%
No	1	9%
NA.	0	-

Moving to GLH/ Genomic hubs - KIT pyrosequencing

Moving to GLH/ Genomic hubs - KIT pyrosequencing	Overall	
	n	% (N = 11)
N/A	10	91%
No	1	9%
NA.	0	-

Current Average Turnaround time (calendar days) - KIT pyrosequencing

Current Average Turnaround time (calendar days) - KIT pyrosequencing	Overall	
	n	% (N = 10)
N/A	10	100%
NA.	1	-

Reflex at diagnosis - BRAF FISH

Reflex at diagnosis - BRAF FISH	Overall	
	n	% (N = 11)
N/A	10	91%
Yes	1	9%
NA.	0	-

Testing at progression/ relapse/ other post Dx timepoints - BRAF FISH

Testing at progression/ relapse/ other post Dx timepoints - BRAF FISH	Overall	
	n	% (N = 11)
N/A	10	91%
No	1	9%
NA.	0	-

Performed by pathology lab - BRAF FISH

Performed by pathology lab - BRAF FISH	Overall	
	n	% (N = 11)
N/A	10	91%
Other lab	1	9%
NA.	0	-

Moved to GLH/ Genomic centre - BRAF FISH

Moved to GLH/ Genomic centre - BRAF FISH	Overall	
	n	% (N = 11)
N/A	10	91%
No	1	9%

NA.	0	-

Moving to GLH/ Genomic hubs - BRAF FISH

Moving to GLH/ Genomic hubs - BRAF FISH	Overall	
	n	% (N = 11)
N/A	10	91%
No	1	9%
NA.	0	-

Current Average Turnaround time (calendar days) - BRAF FISH

Current Average Turnaround time (calendar days) - BRAF FISH	Overall	
	n	% (N = 11)
N/A	10	91%
Not known	1	9%
NA.	0	-

Numerical Data **Grouped data - if applicable**

11.a.i. Breast cancer: HR

11.a.i. Breast cancer: HR	Overall	
	n	% (N = 9)
No	4	44%
Yes	5	56%
NA.	0	-

11.a.i. Breast cancer: PGR

11.a.i. Breast cancer: PGR	Overall	
	n	% (N = 9)
No	3	33%
Yes	6	67%
NA.	0	-

11.a.i. Breast cancer: HER2

11.a.i. Breast cancer: HER2	Overall	
	n	% (N = 9)
No	3	33%
Yes	6	67%
NA.	0	-

11.a.i. Other

11.a.i. Other	Overall	
	n	% (N = 9)
N/A	8	89%
PDL1 for Triple neagtive BC on request	1	11%
NA.	0	-

11.a.i. NA

11.a.i. NA	Overall	
	n	% (N = 9)
No	6	67%
Yes	3	33%
NA.	0	-

11.a.ii. Lung Cancer: PD-L1

11.a.ii. Lung Cancer: PD-L1	Overall	
	n	% (N = 15)
No	2	13%
Yes	13	87%
NA.	0	-

11.a.ii. Lung Cancer: EGFR

11.a.ii. Lung Cancer: EGFR	Overall	
	n	% (N = 15)
No	2	13%
Yes	13	87%
NA.	0	-

11.a.ii. Lung Cancer: ALK

11.a.ii. Lung Cancer: ALK	Overall	
	n	% (N = 15)
No	2	13%
Yes	13	87%
NA.	0	-

11.a.ii. Lung Cancer: BRAF

11.a.ii. Lung Cancer: BRAF	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

11.a.ii. Lung Cancer: ROS1

11.a.ii. Lung Cancer: ROS1	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%
NA.	0	-

11.a.ii. Lung Cancer: RET

11.a.ii. Lung Cancer: RET	Overall	
	n	% (N = 15)
No	9	60%
Yes	6	40%
NA.	0	-

11aii Other

11aii Other	Overall	
	n	% (N = 15)
KRAS	2	13%

KRAS, NTRK	1	7%
N/A	11	73%
T790M	1	7%
NA.	0	-

11.a.ii. NA

11.a.ii. NA	Overall	
	n	% (N = 15)
No	13	87%
Yes	2	13%
NA.	0	-

11.a.iii Melanoma: BRAF

11.a.iii Melanoma: BRAF	Overall	
	n	% (N = 11)
No	1	9%
Yes	10	91%
NA.	0	-

11.a.iii Other

11.a.iii Other	Overall	
	n	% (N = 11)
N/A	11	100%
NA.	0	-

11.a.iii NA

11.a.iii NA	Overall	
	n	% (N = 11)
No	10	91%
Yes	1	9%
NA.	0	-

11.b.

11.b.	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

11.b. Specify

11.b. Specify	Overall	
	n	% (N = 7)
Mix, Pathology lab + GLH	4	57%
Mix, Pathology lab + GLH + Other external lab	1	14%
Mix, Pathology lab + Other external lab	1	14%
Other external lab	1	14%
NA.	8	-

11.c.

11.c.	Overall	
	n	% (N = 15)
Both depending on target + NGS locally would be preferred	1	7%
Both IHC and RT-PCR depending on target	9	60%
IHC	2	13%
IHC + NGS	1	7%
IHC + Other not specified	1	7%
RT-PCR	1	7%
NA.	0	-

11.d.

11.d.	Overall	
	n	% (N = 15)
GLH	2	13%
N/A	1	7%
NHS Trust	9	60%
NHS Trust + GLH	3	20%
NA.	0	-

11.e

11.e	Overall	
	n	% (N = 15)
N/A	2	13%
No	3	20%
Yes	10	67%
NA.	0	-

12. Breast

12. Breast	Overall
	N = 15
Mean	85
SD	36.7
Median	100
IQR	100 to 100
Range	10 to 100
NA.	9

12. Melanoma

12. Melanoma	Overall
	N = 15
Mean	37.2
SD	38.1
Median	20
IQR	5 to 80
Range	5 to 100
NA.	6

12. Lung

12. Lung	Overall
	N = 15
Mean	69.1
SD	33.4
Median	75
IQR	50 to 100
Range	5 to 100
NA.	1

13.a. Please describe the process for request of archival tissue:

13.a. Please describe the process for request of archival tissue:	Overall	
	n	% (N = 15)
Complete request form, retrieval from off-site storage for older tissues (over 2 years). Onsite if more recent	1	7%
Need to request samples (book in/out)	1	7%
Online request for retrieval (storage site not specified)	1	7%
Request from pathology team storage site not specified	1	7%
Request to audit team, retrieval from offsite storage	1	7%
Request to pathology team, selection and request of the block, can be onsite or offsite (older samples)	1	7%
Requested from archival team, Retrieval from off-site storage for older tissues (over 4 years). Onsite if more recent	1	7%
Requested, Retrieval from onsite or offsite, often tissue blocks	1	7%
Requested, Retrieval from onsite storage	1	7%
Retrieval from off-site storage for older tissues, Onsite if more recent	1	7%
Retrieval from onsite storage	1	7%
Selection and request of tissue, Retrieval from off-site storage	1	7%
System based request, retrieval from off-site storage for older tissues (over 5 years). Onsite if more recent	1	7%
Up to 2 years request from onsite, after 2 years, Request from offsite storage.	1	7%
Up to 2 years Request from onsite, after 2 years, request from offsite storage.	1	7%
NA.	0	-

13.a. Please describe the process for request of archival tissue:

13.a. Please describe the process for request of archival tissue:	Overall	
	n	% (N = 15)
Request	/	/
Form	1	7%
Online	1	7%
System based	1	7%
To archival team	1	7%
To pathology team	2	13%
To audit team	1	7%
Not specified	8	53%
Retrieval	/	/
From onsite storage (only)	2	13%
From offsite storage (only)	2	13%
Onsite (recent) - Offsite (after 2 years)	3	20%
Onsite (recent) - Offsite (after 4 years)	1	7%
Onsite (recent) - Offsite (after 5 years)	1	7%
Onsite (recent) - Offsite (older - unspecified)	3	20%
Not specified	3	20%
NA.	0	-

* Request and Retrieval not mutually exclusive (but respectively mutually exclusive within)

13.b. Describe the specific challenges with archival tissue that may exists for Lung, Breast or Melanoma?

13.b. Describe the specific challenges with archival tissue that may exists for Lung, Breast or Melanoma?	Overall	
	n	% (N = 15)
Additional administration, Unpredictable sample quality, Frequent failure of lung cancer tissue	1	7%
Difficulties with sample retrieval, Hard to access or lost samples	1	7%
DNA degradation, Overfixed tissue	1	7%
Loss of tissue sample, Sample quality for lung and melanoma	1	7%
None	1	7%
Sample quality for lung, Small sample size, Loss of tissue sample	1	7%
Sample size with lung cancer	2	13%
Small sample (for lung cancer)	1	7%
Small sample (for lung cancer), Logistics issues with offsite storage	1	7%
Small sample size	1	7%
Small sample size, Cost and resources	1	7%
Small samples, Insufficient sample available, TAT for retrival of offsite stored samples, Cost	1	7%
Time to retrieve from offsite	2	13%
NA.	0	-

13.b. Describe the specific challenges with archival tissue that may exists for Lung, Breast or Melanoma?

13.b. Describe the specific challenges with archival tissue that may exists for Lung, Breast or Melanoma?	Overall	
	n	% (N = 15)
Technical (sample quality, sample quantity, failure rates)	11	
Logistics (additional admin, loss of sample, difficulty with retrieval, cost, turnaround time)	9	
None	1	

13.c.i. Breast

13.c.i. Breast	Overall
	N = 15
Mean	5.2
SD	6.7
Median	2.2
IQR	1.1 to 6.5
Range	0 to 17.5
NA.	7

13.c.ii. Lung

13.c.ii. Lung	Overall
	N = 15
Mean	2.5
SD	3.4
Median	1.5
IQR	1.2 to 2.5
Range	0 to 14
NA.	0

13.c.iii. Melanoma

13.c.iii. Melanoma	Overall
	N = 15
Mean	4.5

SD	5.8
Median	2
IQR	1.5 to 4.2
Range	0 to 17.5
NA.	4

13.d. Sample quality

13.d. Sample quality	Overall	
	n	% (N = 15)
No	8	53%
Yes	7	47%
NA.	0	-

13.d. Additional resource requirements

13.d. Additional resource requirements	Overall	
	n	% (N = 15)
No	9	60%
Yes	6	40%
NA.	0	-

13.d. Processing issues

13.d. Processing issues	Overall	
	n	% (N = 15)
No	14	93%
Yes	1	7%
NA.	0	-

13.d. Transport

13.d. Transport	Overall	
	n	% (N = 15)
No	11	73%
Yes	4	27%
NA.	0	-

13.d. Other What are the challenges with archival tissue for genomics at GLH?

13.d. Other What are the challenges with archival tissue for genomics at GLH?	Overall	
	n	% (N = 5)
Administration burden	2	40%
Retrieval	1	20%
Small sample size	2	40%
NA.	10	-

14.a. Do you currently offer molecular testing of liquid biopsies at your lab?
EGFR only ☐ No ☐

14.a.	Overall	
	n	% (N = 15)
EGFR only	2	13%
EGFR, BRAF, RET, MET	1	7%
EGFR, KIT, BRAF, KRAS, RAS - VERY FEW REQUESTS. NGS VALIDATED BY PLASMA	1	7%
No	11	73%
NA.	0	-

14.b.Are there any other molecular liquid biopsies performed at your lab? If so, which one(s)and for which cancer types?
No ☐
Yes ☐_____

14.b.	Overall	
	n	% (N = 15)
EGFR only	2	13%
EGFR, BRAF, RET, MET	1	7%
EGFR, KIT, BRAF, KRAS, RAS - VERY FEW REQUESTS. NGS VALIDATED BY PLASMA	1	7%
No	11	73%
NA.	0	-

14.c. What do you foresee will be the use of liquid biopsy within the diagnostic pathway?
14.c. For all testing

14.c. For all testing	Overall	
	n	% (N = 15)
No	14	93%
Yes	1	7%
NA.	0	-

14.c. In addition to tissue testing (same targets)

14.c. In addition to tissue testing (same targets)	Overall	
	n	% (N = 15)
No	2	13%
Yes	13	87%
NA.	0	-

14.c. If a suitable tissue sample is not available

14.c. If a suitable tissue sample is not available	Overall	
	n	% (N = 15)
No	6	40%
Yes	9	60%
NA.	0	-

14.c. Upon progression only

14.c. Upon progression only	Overall	
	n	% (N = 15)
No	12	80%
Yes	3	20%
NA.	0	-

14.c. For specific tests only i.e.

14.c. For specific tests only i.e.	Overall	
	n	% (N = 15)
Yes (not specified)	1	7%
As clinically relevant	2	13%
No	12	80%
NA.	0	-

14.c. For panel testing

14.c. For panel testing	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

14.c. Not used

14.c. Not used	Overall	
	n	% (N = 15)
No	15	100%
NA.	0	-

14.d. What are the challenges with liquid biopsies?

14.d. What are the challenges with liquid biopsies?	Overall	
	n	% (N = 14)
Administrative burden, Pathway integration	1	7%
Report preparation, Pathway integration	1	7%
Sensitivity and Specificity	1	7%
Sensitivity, Funding	1	7%
Sensitivity, Limited range of testing methods	2	14%
Sensitivity, Pathway integration	1	7%
Sensitivity, Sample preparation, Interpretation of results	1	7%
Sensitivity, Variable levels of ctDNA in blood	3	21%
Sensitivity, Variable levels of ctDNA in blood, Interpretation of results	1	7%
Sensitivity, Variable levels of ctDNA in blood, Limited range of testing methods	1	7%
Technology, Validation, Interpretation of results (eg MRD)	1	7%
NA.	1	-

14.d. What are the challenges with liquid biopsies?	Overall	
	n	% (N = 14)
Technical issues (Poor sensitivity, variable levels of ctDNA in sample, limited technology/testing options)	12	
Logistical issues (additional admin, pathway integration, funding, results interpretation)	7	
NA	1	

15. Are you currently developing any other molecular tests for Lung, Breast or Melanoma?

15. Are you currently developing any other molecular tests for Lung, Breast or Melanoma?	Overall	
	n	% (N = 15)
Acquiring Genexus platform	2	13%
Acquiring Genexus platform, NGS for Lung Cancer genomics, IHC for BRAF in melanoma	1	7%
Acquiring Genexus platform, NGS locally for urgent Lung cancer, FISH	1	7%
BAP 1 - Immuno stain for Meso and melanomas	1	7%
IHC for BRAF in melanoma	1	7%
NGS locally	2	13%
No	7	47%
NA.	0	-

15. Are you currently developing any other molecular tests for Lung, Breast or Melanoma?	Overall	
	n	% (N = 15)
IHC	3	
NGS technologies	6	
Other	1	
None	7	

16. Timelines for implementation

16. Timelines for implementation	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

16. Test development

16. Test development	Overall	
	n	% (N = 15)
No	11	73%
Yes	4	27%
NA.	0	-

16. Test validation

16. Test validation	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%
NA.	0	-

16. Administration

16. Administration	Overall	
	n	% (N = 15)
No	6	40%
Yes	9	60%
NA.	0	-

16. Funding / Resource allocation

16. Funding / Resource allocation	Overall	
	n	% (N = 15)
No	2	13%
Yes	13	87%
NA.	0	-

16. Communication

16. Communication	Overall	
	n	% (N = 15)
No	11	73%
Yes	4	27%
NA.	0	-

17. Respiratory physicians / Pulmonologists

17. Respiratory physicians / Pulmonologists	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

17. Surgeon

17. Surgeon	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%
NA.	0	-

17. Oncologist

17. Oncologist	Overall	
	n	% (N = 15)
Yes	15	100%
NA.	0	-

17. MDT Coordinator

17. MDT Coordinator	Overall	
	n	% (N = 15)
No	6	40%
Yes	9	60%
NA.	0	-

17. Clinical nurse specialist

17. Clinical nurse specialist	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

17. Other

17. Other	Overall	
	n	% (N = 5)
Dermatologists	3	60%
Pathologists	1	20%
Radiologists	1	20%
NA.	10	-

18. Do you regularly attend MDT?

18. Do you regularly attend MDT?	Overall	
	n	% (N = 15)
No	1	7%
Yes	14	93%
NA.	0	-

19. Do you discuss results at standard MDTs?

19. Do you discuss results at standard MDTs?	Overall	
	n	% (N = 15)
Yes	15	100%
NA.	0	-

20. Do you have a molecular specific MDTs?

20. Do you have a molecular specific MDTs?	Overall	
	n	% (N = 15)
No	12	80%
Yes	3	20%
NA.	0	-

21. Respiratory physicians / Pulmonologists

21. Respiratory physicians / Pulmonologists	Overall	
	n	% (N = 15)
No	10	67%

Yes	5	33%
NA.	0	-

21. Surgeon

21. Surgeon	Overall	
	n	% (N = 15)
No	11	73%
Yes	4	27%
NA.	0	-

21. Administrator

21. Administrator	Overall	
	n	% (N = 15)
No	12	80%
Yes	3	20%
NA.	0	-

21. Pathologists

21. Pathologists	Overall	
	n	% (N = 15)
Yes	15	100%
NA.	0	-

21. Clinical scientist (genomics)

21. Clinical scientist (genomics)	Overall	
	n	% (N = 15)
No	12	80%
Yes	3	20%
NA.	0	-

21. Oncologist

21. Oncologist	Overall	
	n	% (N = 15)
No	5	33%
Yes	10	67%
NA.	0	-

21. Other

21. Other	Overall	
	n	% (N = 2)
CNS	1	50%
CNS, Dermatologist	1	50%
NA.	13	-

22. Email

22. Email	Overall	
	n	% (N = 15)
No	1	7%
Yes	14	93%
NA.	0	-

22. Webpage

22. Webpage	Overall	
	n	% (N = 15)
No	13	87%
Yes	2	13%
NA.	0	-

22. Hospital Newsletter

22. Hospital Newsletter	Overall	
	n	% (N = 15)
No	14	93%
Yes	1	7%
NA.	0	-

22. MDT meeting

22. MDT meeting	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%
NA.	0	-

22. Other

22. Other	Overall	
	n	% (N = 7)
Focus groups, Educational webinars	1	14%
Informal discussions	2	29%
Informal discussions, Conferences	1	14%
Informal discussions, Meetings	1	14%
Phone	2	29%
NA.	8	-

23. No

23. No	Overall	
	n	% (N = 15)
No	1	7%
Reference to available targeted therapies only	2	13%
Reference to published therapy area guidelines only	3	20%
Yes	9	60%
NA.	0	-

23. Other specify

23. Other specify	Overall	
	n	% (N = 6)
Cross-reference literature for less known alterations	1	17%
Drug classes only - no specified named treatments	1	17%
Drug classes only - no specified named treatments, Not for melanoma	1	17%
Less for melanoma	1	17%
Notes on whether sentizing mutation or not (i.e. EGFR)	1	17%
Variant classification would be a good to include but not done at the moment	1	17%
NA.	9	-

24. What impact has COVID-19 had on your current services?

24. What impact has COVID-19 had on your current services?	Overall	
	n	% (N = 15)
High impact	6	40%
Medium impact	5	33%
Minimal or no impact	4	27%
NA.	0	-

24. Please describe if medium or high impact

24. Please describe if medium or high impact	Overall	
	n	% (N = 12)
Backlog (Breast + Melanoma), Increased workload (Breast + Melanoma)	1	8%
Backlog of patient presenting with later diagnosis	1	8%
Delays in getting specimens	1	8%
Impact on referal services	1	8%
Increase in workload	1	8%
Increase workload from backlog	1	8%
Less staff, Increase in workload	2	17%
Less staff, Increase in workload, Backlog, Reallocation of consumables	1	8%
Number of specimens dicreased early on, Normal numbers now	1	8%
Reduced capacity early pandemic, Backlog on current testing service	1	8%
Slight increase in current workload particularly for urgent services	1	8%
NA.	3	-

24. Please describe if medium or high impact of COVID	Overall	
	n	% (N = 12)
Staffing (reduced during COVID)	4	
Workloads (lower presentation, delays in referral, backlogs)	12	
Other	1	
NA	3	

25. What impact has the roll out of the GMS and GLH had on your current services (positiveand/or negative)?

25. What impact has the roll out of the GMS and GLH had on your current services (positiveand/or negative)?	Overall	
	n	% (N = 15)
High impact	8	53%
Medium impact	4	27%
Minimal or no impact	1	7%
N/A	2	13%
NA.	0	-

25. Please describe

25. Please describe	Overall	
	n	% (N = 15)
N/A	1	7%
Negative - Cost, Funding issues / Positive - GLH improved TAT (due to salvage pathway using Genexus), more GLH usage leading to less wait for batching	1	7%
Negative - Extra workload	1	7%
Negative - GLH not running, No local funding, Incomplete testing, Poor TAT, pathway not streamlined, Roles unclear, Higher staff turnover, Increased resource requirements	1	7%
Negative - Increased administrative burden, Increase resource, Poor compatibility of IT system	1	7%
Negative - Loss of local genomic lab, Service moving further from patient, Pathway not streamlined	1	7%
Negative - No pathology input into new service	1	7%
Negative - Poor TAT, Higher sample quality requirements for NGS, High failure rate, Poor compatibility of IT system	1	7%
Negative - Poor TAT, Inefficient results reporting, Hinderance of local research projects	1	7%
Negative - Poor TAT, Logistical burden / Positive - Improved failure rate	1	7%
Negative - Service moving further from patient, Pathway not streamlined, Funding, Lack of pathology acknowledgement, Lack of collaboration	1	7%
Negative - TAT, Sample quantity requirement is higher, Pathway not streamlined, Inefficient results reporting (too complicated)	1	7%
Positive - Funding, Efficient test delivery, Higher sequence coverage	1	7%
Positive - Lung streamlined pathway (reflex), Good communication / Negative - Melanoma + Breast not streamlined, Poor TAT, Higher tissue quality requirements, Administrative burden, Lack of collaboration, Poor IT integration	1	7%
Positive - No extra workload	1	7%
NA.	0	-

24. Please describe if medium or high impact of GLH/GMS	Overall	
	n	% (N = 15)
Negative	/	/
Technical (Higher tissue quality requirements, High failure rates, incomplete testing)	3	
Logistics (Funding issues, TAT, increase resource requirements, increased admin, poor compatibility with IT, pathway not streamlined and further from patient, lack of collaboration)	12	
NA		
Positive	/	/
Technical (Improved TAT due to new NGS locally, Improved failure rates, Higher sequence coverage)	2	
Logistics (Funding, efficiency/streamlined pathway, communication)	5	
NA		

26. What impact will the roll out of the GMS and GLH had on your future services (positive and/ornegative)?

26. What impact will the roll out of the GMS and GLH had on your future services (positive and/ornegative)?	Overall	
	n	% (N = 12)
High impact	8	67%
Minimal or no impact	3	25%
N/A	1	8%

NA.	3	-

26. Please describe

26. Please describe	Overall	
	n	% (N = 15)
Negative - Administrative burden, Inefficient reporting	1	7%
Negative - Division of pathology and genomics, Longer TAT, Higher tissue quality requirements, Administrative burden	1	7%
Negative - Longer TAT	1	7%
Negative - Longer TAT (Lung + Melanoma)	1	7%
Negative - Longer TAT, Lack of guidance, May need to find alternatives to GLH / Positive - In melanoma could improve dianosis and prognosis	1	7%
Negative - Service not streamlined, Funding concerns	1	7%
N/A	1	7%
Positive - Increased use of GLH, More capacity locally for urgent samples	1	7%
Positive - Reduced workload, More capacity for urgent samples, Complex cases being handled by GLH	1	7%
Positive - Will overcome sample quanitity constraints / Negative - Logistical burden	1	7%
Unsure	4	27%
Unsure / Positive - Save money, Standardise results	1	7%
NA.	0	-

24. Please describe if medium or high impact of GLH/GMS	Overall	
	n	% (N = 15)
Negative	/	/
Technical (higher tissue requirements)	1	
Logistics (additional admin, inefficient reporting, devision of pathway, longer turnaround times, lack of guidance, funding concerns)	7	
Positive	/	/
Technical	0	
Logistics (more capacity locally for urgent samples, reduced workload)	4	
Other	1	
Unsure	5	33%
N/A	1	7%

27. Sample Preparation

27. Sample Preparation	Overall	
	n	% (N = 15)
No	2	13%
Yes	13	87%
NA.	0	-

27. Test assignment (reflexive)

27. Test assignment (reflexive)	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%
NA.	0	-

27. Conducting testing: All

27. Conducting testing: All	Overall	
	n	% (N = 15)
No	8	53%
Yes	7	47%
NA.	0	-

27. Conducting testing: Cellular

27. Conducting testing: Cellular	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

27. Conducting testing: Salvage

27. Conducting testing: Salvage	Overall	
	n	% (N = 15)
No	8	53%
Yes	7	47%
NA.	0	-

27. Conducting testing: Urgent or first line testing

27. Conducting testing: Urgent or first line testing	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

27. Data analysis

27. Data analysis	Overall	
	n	% (N = 15)
No	6	40%
Yes	9	60%
NA.	0	-

27. Report creation

27. Report creation	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

27. Education Training

27. Education Training	Overall	
	n	% (N = 15)
No	2	13%

Yes	13	87%
NA.	0	-

27. Where do you see the role of regional pathology centres in the optimal delivery of the GMS?

Other

27. Where do you see the role of regional pathology centres in the optimal delivery of the GMS? Other	Overall	
	n	% (N = 3)
Intergrate diagnostic information from different sources	1	33%
Providing prognostic and predictive factors on a timely basis	1	33%
Role unclear	1	33%
NA.	12	-

28. How do you currently work with your GLH? i.e. access to tissue, sample preparation, salvage/urgent testing, preparation of reports, etc.

28. How do you currently work with your GLH? i.e. access to tissue, sample preparation, salvage/urgent testing, preparation of reports, etc.	Overall	
	n	% (N = 13)
Collaborate on issues	1	8%
Collaboration on region wide issues, Testing, Test development / provide validation set for new indications, Report generation and integration	1	8%
None	1	8%
Pathology integrates GLH report into their local reporting system	1	8%
Prepare tissue sections / samples for GLH, GLH provides molecular report	2	15%
Prepare tissue sections / samples for GLH, GLH provides molecular report, Pathology to input report on local system	2	15%
Prepare tissue sections / samples for GLH, Urgent testing 1L, Training GLH scientists	1	8%
Request test, Prepare tissue sections / samples for GLH, GLH provides molecular report	1	8%
Request test, prepare tissue sections / samples for GLH, GLH provides molecular report, Collaborate on issues	1	8%
Request test, Prepare tissue sections / samples for GLH, GLH provides molecular report, Pathology authorise the final report	1	8%
Request testing, Prepare tissue sections / samples for GLH, GLH provides molecular report	1	8%
NA.	2	-

28. How do you currently work with your GLH? i.e. access to tissue, sample preparation, salvage/urgent testing, preparation of reports, etc.

28. How do you currently work with your GLH? i.e. access to tissue, sample preparation, salvage/urgent testing, preparation of reports, etc.	Overall	
	n	% (N = 13)
Collaborate on issues	3	23%
Test development / provide validation set for new indications	1	8%
Report generation and integration	1	8%
Pathology integrates GLH report into their local reporting system	1	8%
Prepare tissue sections / samples for GLH	9	69%
GLH provides molecular report	8	62%
Pathology to input report on local system	1	8%
Urgent testing 1L	1	8%
Training GLH scientists	1	8%
Request test	4	31%
Pathology authorise the final report	1	8%
Testing	1	8%
None	1	8%
NA.	2	-

* Categories not mutually exclusive

29. Sample Quality

29. Sample Quality	Overall	
	n	% (N = 15)
High impact	7	47%
Medium impact	5	33%
Minimal or no impact	3	20%
NA.	0	-

29. Transportation

29. Transportation	Overall	
	n	% (N = 15)
High impact	5	33%
Medium impact	3	20%
Minimal or no impact	7	47%
NA.	0	-

29. Ordering GLH tests

29. Ordering GLH tests	Overall	
	n	% (N = 15)
High impact	1	7%
Medium impact	4	27%
Minimal or no impact	9	60%
Not applicable	1	7%
NA.	0	-

29. Admin

29. Admin	Overall	
	n	% (N = 15)
High impact	6	40%
Medium impact	5	33%
Minimal or no impact	4	27%
NA.	0	-

29. Testing options/capabilities

29. Testing options/capabilities	Overall	
	n	% (N = 15)
High impact	6	40%
Medium impact	2	13%
Minimal or no impact	5	33%
Not applicable	2	13%
NA.	0	-

29. Data analysis/ bioinformatics

29. Data analysis/ bioinformatics	Overall	
	n	% (N = 14)
High impact	2	14%
Medium impact	2	14%

Minimal or no impact	7	50%
Not applicable	3	21%
NA.	1	-

29. IT requirements/ compatibility

29. IT requirements/ compatibility	Overall	
	n	% (N = 15)
High impact	5	33%
Medium impact	6	40%
Minimal or no impact	3	20%
Not applicable	1	7%
NA.	0	-

29. Reporting

29. Reporting	Overall	
	n	% (N = 14)
High impact	1	7%
Medium impact	5	36%
Minimal or no impact	8	57%
NA.	1	-

29. Education/training

29. Education/training	Overall	
	n	% (N = 15)
High impact	2	13%
Medium impact	6	40%
Minimal or no impact	6	40%
Not applicable	1	7%
NA.	0	-

29.Resource/Capacity

29.Resource/Capacity	Overall	
	n	% (N = 15)
High impact	7	47%
Medium impact	7	47%
Minimal or no impact	1	7%
NA.	0	-

29. Funding

29. Funding	Overall	
	n	% (N = 15)
High impact	7	47%
Medium impact	4	27%
Minimal or no impact	3	20%
Not applicable	1	7%
NA.	0	-

29. What do you see as the current barriers for optimal delivery of the GMS?

Other

29. What do you see as the current barriers for optimal delivery of the GMS? Other	Overall	
	n	% (N = 5)
Communication	1	20%
Pathology having control/ pathway integration - high impact	1	20%
Poor service (no access)	1	20%
Recognition	1	20%
TATs - High impact	1	20%
NA.	10	-

30. Do you have other concerns regarding the delivery of this service?

30. Do you have other concerns regarding the delivery of this service?	Overall	
	n	% (N = 15)
No	5	33%
Yes	10	67%
NA.	0	-

30. Do you have other concerns regarding the delivery of this service?

30. Do you have other concerns regarding the delivery of this service?	Overall	
	n	% (N = 11)
Funding, TAT	1	9%
Insufficient training on GLH, New technology implementation	1	9%
Outdated technology, Inefficient service	1	9%
Poor communication, Service not flexible	1	9%
Resource, Capacity, Collaboration	1	9%
Service moving further from patient, Pathway not streamlined, More collabotration and flexibility required	1	9%
Service moving further from patient, TAT, Sample flow not streamlined, Pathway not streamlined, Service not flexible	1	9%
TAT, Pathway not streamlined	1	9%
TAT, Pathway not streamlined, Poor communication, Poor collaboration, Need for clear procedures, Need for clear interpretable reports	1	9%
TAT, Workload, Heterogeneity across GLHs	1	9%
Uneven experience and expertise across network, Failure rates	1	9%
NA.	4	-

24. Please describe if medium or high impact of GLH/GMS	Overall	
	n	% (N = 11)
Technical (implementation of new technology, outdated technology, failure rates)	3	
Logistics (Funding, TAT, insufficient training, poor communication, capacity, lack of collaboration, pathway not streamlined, lack of clarity of pathway and roles, heterogeneity in experience and expertise across network)	10	
Other	4	
NA	4	

31. What additional resources are required at local pathology labs to support optimal delivery of this service?

31. What additional resources are required at local pathology labs to support optimal delivery of this service?	Overall	
	n	% (N = 14)
Additional staff (Admin)	1	7%
Additional staff (Admin, Scientist), Additional sample prep resource	1	7%
Additional staff (Admin, Scientist), Improved IT efficiency (for sample tracking and reports), Improved communication with MDT	1	7%
Additional staff (Pathologists, Scientist)	1	7%
Additional staff (Pathologists, Admin, Scientist)	1	7%
Additional staff (Pathologists, Scientist)	1	7%
Additional staff (Pathologists, Scientist), Improve communication and collaboration with GLH	1	7%
Additional staff, Additional admin resource	1	7%
Educational support on sample suitability	1	7%
Funding for local testing, Additional staff (Pathologists)	1	7%
Funding, Additional staff (Admin)	1	7%
More facilities	1	7%
None	2	14%
NA.	1	-

24. Please describe if medium or high impact of GLH/GMS	Overall	
	n	% (N = 14)
Staffing	11	
Funding	2	
Other		
None	2	
NA	1	

Regional pathology centre - New treatment trial results

Regional pathology centre - New treatment trial results	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

Regional pathology centre - Optimal reporting

Regional pathology centre - Optimal reporting	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

Regional pathology centre - Guideline reviews/updates

Regional pathology centre - Guideline reviews/updates	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%
NA.	0	-

Regional pathology centre - Understanding the new molecular testing pathway

Regional pathology centre - Understanding the new molecular testing pathway	Overall	
	n	% (N = 15)
No	1	7%
Yes	14	93%
NA.	0	-

Regional pathology centre - Best practice sharing across lab

Regional pathology centre - Best practice sharing across lab	Overall	
	n	% (N = 15)
No	1	7%
Yes	14	93%
NA.	0	-

Regional pathology centre - Cross-functional education with clinicians

Regional pathology centre - Cross-functional education with clinicians	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%
NA.	0	-

Regional pathology centre - Other

Regional pathology centre - Other	Overall	
	n	% (N = 15)
Development and support of molecular MDTs	1	7%
New molecular markers	1	7%
No	13	87%
NA.	0	-

DGH pathology labs - New treatment trial results

DGH pathology labs - New treatment trial results	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

DGH pathology labs - Optimal reporting

DGH pathology labs - Optimal reporting	Overall	
	n	% (N = 15)
No	7	47%

Yes	8	53%
NA.	0	-

DGH pathology labs - Guideline reviews/updates

DGH pathology labs - Guideline reviews/updates	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

DGH pathology labs - Understanding the new molecular testing pathway

DGH pathology labs - Understanding the new molecular testing pathway	Overall	
	n	% (N = 15)
No	5	33%
Yes	10	67%
NA.	0	-

DGH pathology labs - Best practice sharing across lab

DGH pathology labs - Best practice sharing across lab	Overall	
	n	% (N = 15)
No	5	33%
Yes	10	67%
NA.	0	-

DGH pathology labs - Cross-functional education with clinicians

DGH pathology labs - Cross-functional education with clinicians	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

DGH pathology labs - Other

DGH pathology labs - Other	Overall	
	n	% (N = 15)
Development and support of molecular MDTs	1	7%
importance of tissue stewardship	1	7%
No	13	87%
NA.	0	-

Surgeons - Interpreting reports/results

Surgeons - Interpreting reports/results	Overall	
	n	% (N = 15)
No	9	60%
Yes	6	40%
NA.	0	-

Surgeons - Overview of different types of tests

Surgeons - Overview of different types of tests	Overall	
	n	% (N = 15)
No	7	47%
Yes	8	53%
NA.	0	-

Surgeons - Tissue requirements

Surgeons - Tissue requirements	Overall	
	n	% (N = 15)
No	5	33%
Yes	10	67%
NA.	0	-

Surgeons - Patient information – testing and results

Surgeons - Patient information – testing and results	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

Surgeons - Other

Surgeons - Other	Overall	
	n	% (N = 15)
new tests for neo/adjuvant	1	7%
No	14	93%
NA.	0	-

CNS - Interpreting reports/results

CNS - Interpreting reports/results	Overall	
	n	% (N = 15)
No	5	33%
Yes	10	67%
NA.	0	-

CNS - Overview of different types of tests

CNS - Overview of different types of tests	Overall	
	n	% (N = 15)
No	5	33%
Yes	10	67%
NA.	0	-

CNS - Tissue requirements

CNS - Tissue requirements	Overall	
	n	% (N = 15)
No	6	40%
Yes	9	60%
NA.	0	-

CNS - Patient information – testing and results

CNS - Patient information – testing and results	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%

NA.	0	-

CNS - Other

CNS - Other	Overall	
	n	% (N = 15)
No	15	100%
NA.	0	-

Clinicians - Interpreting reports/results

Clinicians - Interpreting reports/results	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

Clinicians - Overview of different types of tests

Clinicians - Overview of different types of tests	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

Clinicians - Tissue requirements

Clinicians - Tissue requirements	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

Clinicians - Patient information – testing and results

Clinicians - Patient information – testing and results	Overall	
	n	% (N = 15)
No	2	13%
Yes	13	87%
NA.	0	-

Clinicians - Other

Clinicians - Other	Overall	
	n	% (N = 15)
Lab tours: Understanding of how pathology works, requirements for planning the service	1	7%
No	13	87%
Understanding of what is being ordered	1	7%
NA.	0	-

34. Digital education

34. Digital education	Overall	
	n	% (N = 15)
No	3	20%
Yes	12	80%
NA.	0	-

34. Paper education

34. Paper education	Overall	
	n	% (N = 15)
No	11	73%
Yes	4	27%
NA.	0	-

34. HCP Portal/Websites

34. HCP Portal/Websites	Overall	
	n	% (N = 15)
No	9	60%
Yes	6	40%
NA.	0	-

34. Educational Meetings: virtual

34. Educational Meetings: virtual	Overall	
	n	% (N = 15)
No	4	27%
Yes	11	73%
NA.	0	-

34. Educational Meetings: in person

34. Educational Meetings: in person	Overall	
	n	% (N = 15)
No	6	40%
Yes	9	60%
NA.	0	-

34. Preceptorships

34. Preceptorships	Overall	
	n	% (N = 15)
No	11	73%
Yes	4	27%
NA.	0	-